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Abstract 
Stress is a state that triggers change in normal physiology and recognized by human body and brain 
as an unfavorable event causing concern, worry or anxiety. It may vary from physical, metabolic, 
physiological or emotional often culminating into wide range of ailments that may range from 
common cold, decline in functional efficacy of body systems or even cancer. A variety of natural 
compounds have been used for anti-stress and disease preventive potentials in worldwide 
traditional home medicine systems. They have recently attracted attention in research laboratories 
to dissect their mode of action to promote safe and economic drug development. Cancer is one of 
the most important healthcare matters in question, with the worst prognosis but the best possibilities 
for scientific development. It is uncontrolled proliferation of abnormal cells, resulting from a host 
of mutations developing into functional disabilities. Environmental insults from the daily life like 
heavy metal, smoke, anger, hypoxia, oxidizers and radiations play vital role in worsening the 
prognosis of cancer and causes metastasis. Its likeliness to increase in the future to cause global 
havoc designates it as an epidemic. Cancer development requires urgent intervention. Past few 
decades have witnessed extensive research to challenge carcinogenesis.  Treatment involving 
synthetic discipline is often associated with severe adverse effects, or even worsened prognosis. 
Cancer chemotherapy is toxic and complicated by undesirable secondary effects. Metastasis, 
cancer cell’s ability to move from the primary site and invade distant tissues in the body, 
accompanied by emergence of drug resistant variants, is another major hurdle in cancer treatment. 
Accordingly, newer economic and patient friendly anti-metastasis molecules are deemed useful in 
intervention of cancer cell aggressiveness and drug resistant properties.  Many natural substances 
have proved their potential so far. Helicteres angustifolia L. is a shrub that forms a common 
ingredient of several cancer treatment recipes in traditional medicine system both in China and 
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Laos.  In order to investigate molecular mechanisms of its anticancer activity, we prepared aqueous 
extract of Helicteres angustifolia L. Roots (AQHAR) and performed several in vitro assays using 
human normal fibroblasts (TIG-3) and osteosarcoma (U2OS). We found that AQHAR caused 
growth arrest/apoptosis of U2OS cells in a dose-dependent manner. It showed no cytotoxicity to 
TIG-3 cells at doses up to 50 µg/ml. Biochemical, imaging and cell cycle analyses revealed that it 
induces ROS signaling and DNA damage response selectively in cancer cells. The latter showed 
upregulation of p53, p21 and downregulation of Cyclin B1 and phospho-RB. Furthermore, 
AQHAR-induced apoptosis was mediated by increase in pro-apoptotic proteins including cleaved 
PARP, caspases and BAX. Anti-apoptotic protein BCL-2 showed decrease in AQHAR-treated 
U2OS cells. In vivo xenograft tumor assays in nude mice revealed dose-dependent suppression of 
tumor growth and lung metastasis with no toxicity to the animals suggesting that AQHAR could 
be a potent and safe natural drug for cancer treatment. One of the important known bioactives from 
Helicteres angustifolia is Cucurbitacin B. We found that whereas AQHAR was relatively safe to 
the normal cells, Cucurbitacin B was toxic and unsuitable for application in the living tissue for 
medicinal purposes. Here, we have developed a 1:500 molar ratio combination of Cucurbitacin B 
and Withanone (=CucWi-N), and analyzed its anticancer potential using non-small-cell lung cancer 
cells. CucWi-N at this ratio dose was found to be safer to the normal cells than the cancer cells. In 
our initial in silico model, Cucurbitacin B showed prospect to abrogate mortalin-p53 interaction 
(necessary for cancer cell proliferation) and in combination with Withanone had synergistic affinity 
to engage hnRNP-K protein (necessary for cancer cell migration). In in vitro analysis, we found 
that the combination significantly and dose-dependently caused changes at cellular and protein 
level indicating (i) sensitization of cancer cells to environmental stressors (ii) inhibition of stemness 
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and aggressiveness of the cancer cells, and (iii) induction of replicative senescence. We believe 
that CucWi-N is a potential anticancer drug that warrants further mechanistic and clinical studies. 
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1.1 Introduction  
Cancer is a syndrome of diseases wherein the cells upon aberrant mutations/environmental 
stresses witness either the activation of proto-oncogenes or the suppression of tumor suppressor 
proteins. Resultantly, they undergo uncontrolled infinite replication, lose their functional 
characteristics, and exploit their physiological neighbors for nutrients and space.  The process is 
often accompanied with malignant transformation and metastatic spread - EMT [1], especially 
when the availability of resources at a particular cancer niche shortens.  Various mechanisms like 
autocrine and endocrine regulation of growth factors, platelet adhesion, quiescence, cytoskeleton 
rearrangements, cancer cell differentiation, micro metastasis, EMT, angiogenesis and niche 
formation determine the outcome.  WHO data states that the global cancer burden is likely to rise 
to 22 million by 2030 [2], due to a variety of homeostatic insults. Cancer cells operate via various 
molecular mechanisms, popularly categorized as the cell signaling pathways. I here provide an 
outline of the major tumor suppressor and oncogenic pathways, which regulate the process of 
human carcinogenesis. 
Tumor suppressor p53 protein (Fig. 1) is known as the guardian of the genome [3-6].  
External or internal cellular injury to a normal cell activates the p53 tumor suppressor pathway. It 
directs the cell into growth arrest and apoptotic state via activation of several downstream effectors 
including growth arrest (p21WAF1 and others) and apoptosis (BAX, PUMA and others) inducing 
proteins.  Retinoblastoma (RB) protein (Fig. 1) coded by RB1 tumor suppressor gene [7-9]. At the 
G1-S checkpoint, escalated Cyclin D binds with CDK4 leading to pRB phosphorylation, abrogation 
of pRB-E2F complexes and free E2F, which translocate to nucleus and activates genetic 
transcription via polymerase secretion, which is crucial for proliferation. 
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Wnt protein interacts with frizzled receptor extracellularly and deactivates β-catenin-
destruction complex, which is made up of GSK3, Axin, CSK1α, PP2A and APC, coded by their 
respective genes [10].  The complex binds to β-catenin present in the cytoplasm and degrades it via 
phosphorylation-ubiquitination-proteasomal degradation.  Mutations in any of them (ultimately 
resulting into cancer), most frequently in APC, result in faulty complex structure, which fails to 
bind to and degrade β-catenin.  Excess β-catenin translocates to the nucleus, binds with galectin-3, 
interacts with T-cell transcription, lymphoid enhancing transcription factors, and promotes genes, 
which code for cyclin D protein essential for G1/S cell cycle transition.  STAT3 is a latent 
transcriptional factor in the cytoplasm, which is regulated by JAK phosphorylation (Fig. 1) [11-
18]. It directly or indirectly upregulates genes associated with tumor proliferation and survival, and 
constitutes an important intracellular signal transduction pathway in cancer, which regulates cancer 
cell growth and differentiation.  Inactivation or de-phosphorylation of the protein forces cells to 
undergo growth arrest and apoptosis.  
Cancer tissue is fast growing and evading, central mass of which often suffers hypoxia.  
Emergency mechanisms such as HIF signaling get activated, which trigger angiogenesis, metastatic 
spread of disease, and resistance to chemotherapy.  HIF-1 monomer is continuously transcribed 
and translated, and degraded via ubiquitin mediated proteasomal degradation under normoxic 
conditions.  In hypoxic condition, this degradation is downregulated, resulting into accumulation 
of monomer.  Accumulated monomers translocate to the nucleus and dimerize with HIF-1β to form 
a complex, which modulates transcription and translation of the target genes. NFκB proteins 
function as dimeric transcription factors and regulate the expression of genes influencing 
immunological, stress, and inflammatory response [19].  NFκB pathway proteins are normally 
bound to IκB and remain in an inactive state.  Pro-inflammatory cytokines and other mitogens 
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activate IKK complex (IKKβ-IKKα-NEMO), which phosphorylates IκB proteins for its 
ubiquitination and proteasomal degradation.  Free and active NFκB upon further phosphorylation, 
acetylation and glycosylation, translocate to nucleus to induce target gene expression. 
Activated dimer of GFR phosphorylates RAS-GDP complex to RAF-GTP, which via series 
of downstream phosphorylation activates RAF kinase, MEK, MAP kinase and cMYC in cytosol 
and ELK1 in the nucleus (Fig. 1) [20].  ELK1 further activates cFOS transcription, which dimerize 
with cJUN.  Activated cMYC and cJUN-cFOS complex trigger subsequent transcription, which 
are essential for DNA replication, such as cyclin D.  Receptor tyrosine kinase activates PI3K, a 
complex of p85 and p110 proteins [21].  Activated PI3K phosphorylates PIP2 into PIP3, which via 
PDK1 activation phosphorylates AKT.  After downstream signaling involving TSC1/2, Rheb and 
mTORC1 activates p70S6K and 4EBP1, which via estrogen receptor further translate to cell 
survival, growth, proliferation, differentiation, migratory potential and metabolism.  Telomeres are 
specialized chromosome ends in the cells consisting of tightly held specialized and repetitive (10-
15 kb) TTAGGG sequence, and protein caps, which protect chromosomes from terminal fusion 
[22, 23]. Every time a normal cell divides a small portion of the telomeric end gets eroded of about 
50-200 base pairs until the bare chromosomal ends are left. At this stage, cell enters an irreversible 
and non-proliferative phase called replicative senescence.  Most cancer cells acquire the ability to 
synthesize enzyme telomerase, which helps to regenerate telomeric ends. Autophagy is a 
conservation-indicated destructive process, wherein the non-functional or stressed cytoplasmic 
organelles and other constituents are delivered to lysosomes [24]. Lysosome engulfs and digests 
the material, and release energy and other important elements, which may be utilized in cellular 
metabolism. It is frequently found to take place as a response to cellular stress, but skeptical as it 
may be either protective or discretely destructive. It is characterized by the appearance of large 
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cytoplasmic vacuoles or vesicles with up regulation of ATG family proteins viz., LC3II/I, ULK1/2, 
and Beclin1, etc.  Stress stimuli, nutritional imbalance, hypoxia and other chemical mediators like 
ROS and insults to intracellular homeostasis may lead to induction of autophagy response. 
Prevention of production of ROS or catabolic destruction of ROS is explicitly defined as 
the antioxidant mechanism. ROS are charged super-ions, continually generated and released in the 
cells, presenting with vacuolization in cytosol and reaction with biomolecules like cell organelles 
and genetic material to generate peroxides and malondialdehyde. These alter membrane potential 
and signal transduction, and may induce cell offing mechanisms like necrosis, apoptosis and 
autophagy.  ROS generation increases as a result of environment insults like pollution, radiations, 
infestation, etc. Prevention and control of cancer is one of the most expensive and least prolific 
healthcare investments, on top of which it is also burdened with toxic adverse effects associated 
with chemotherapy and radiotherapy.  Use of natural medicines could not only lower the 
expenditure in the disease extensively, but may also bring down the adverse effect rate in clinical 
patients.  Holistic approach (consumption of the natural molecules and relatives in the ratio 
prepared by the nature) for the treatment of cancer, as it is naturally prepared by the nature, could 
be adopted.  Kaefer and Milner enumerated a list of benefits if the treatment of the disease is mainly 
herbal, and their probable role in the cancer [25]. Many biologically active molecules from the 
herbal sources have been identified in the last few decades, which in experiment have potential to 
prevent the disease, control its growth, and possibly eradicated it completely. Cucurbitacin B is 
one of the most extensively studied natural bioactives. 
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Fig. 1. Major cell signaling pathways contributing to cancer, and modulation by Cucurbitacin B.  
Upregulation (✚) and downregulation (-) of protein expression. 
Garg et al. 2018 International Journal of Oncology 52(1): 19-37 
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Chapter 2 
Helicteres angustifolia 
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2.1 Introduction 
Helicteres angustifolia L. (H. angustifolia) is a small shrub widely distributed in slopping 
grassland such as the Southeast China, Laos, Japan, Australia and many Southeast Asian countries. 
The dry root of H. angustifolia, known as “Shan Zhi Ma” in Chinese, has been popularly consumed 
as a medicinal liquor or tea to promote general wellness, and widely used to treat a variety of 
ailments ranging from flu to cancer [26-30]. Although popularly used for health and medicinal 
benefits, the scientific evidence behind their mechanism of action is limited. Previous 
investigations on active phytochemicals in the roots of H. angustifolia have identified various 
chemicals including Cucurbitacins and their derivatives [31, 32] in its extracts that exhibited 
inhibition of growth in a variety of human cancer cells [32-34]. Considering that the water extract 
is more favorable for human consumption, we investigated anticancer potential of aqueous extract 
of H. angustifolia roots (AQHAR) and found, for the first time, that it possesses potent anti-cancer 
activity [29]. In the present study, we demonstrate the mechanism of such anti-cancer activity using 
in vitro cell-based assays, with further validation in the immune-compromised animal model. 
Oxidative stress is characterized by excessive production of reactive oxygen species, which 
oxidizes intra-cellular structures and extinguish their functions. AQHAR induced DNA damage 
and oxidative stress signaling causing death of cancer cells [29]. 
Previously, some studies have reported anti-cancer activity of Cucurbitacin B in different 
types of cancers including liver [35], breast [36], laryngeal [37], brain [38], bone [39] and lung 
[40]. It has been shown to possess anticancer activity either as independent agent, or in synergism 
with other natural or synthetic molecules. Cucurbitacin B has been one of the extensively studied 
small molecules not only for cancer, but also for other ailments. While the therapeutic dose required 
as anti-inflammatory and other complementary conditions is relatively low, cancer essentially 
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requires a high dose as the mainstay of the treatment is to kill the cells. However, the toxicity 
profile of the molecule in the normal human cells has not been significantly explored. 
Cancer cells pose threat to human organ systemic functions because they invade space and 
nutrients, which should ideally be used by the normal cells for growth and positive contribution to 
the health. Cancer cells are often described as the threat that at first sit quietly, learn from the 
surroundings and survive, so that when the time comes they may grow to gluttonous proportion, 
which the normal defense mechanism fails to comprehend, thereby contentedly invading the rights 
from the normal cells. Since the cancer cells are concurrently present with the normal cells in the 
diseased state of the body, it is important to eliminate them without causing much harm to the 
normal tissue. 
Cucurbitacin B is one of the documented primary bioactives found in the roots of H. 
angustifolia [31]. For this reason, we first determined the toxicity profile of Cucurbitacin B for 
human normal lung cells and for a variety of cancer derived cells. We found that Cucurbitacin B 
was toxic to the most of cancer cells and showed moderate toxicity to normal cells as well. It caused 
cellular disruption and forced both the normal and cancer cells into death via series of significant 
and irreversible molecular signaling. Hence, the use of Cucurbitacin B at the cancer-killing dose 
as cancer therapeutics could not be precisely applauded. 
 
2.2 Materials and Methods 
2.2.1 Aqueous extract of H. angustifolia roots (AQHAR), cells and reagents 
The roots of H. angustifolia used in the present study were collected from Vientianei, Laos 
as described earlier [29]. AQHAR (8.4%) was prepared by extraction of dried root powder with 
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distilled water at room temperature [29]. Human cancer and normal cells were obtained from the 
Japanese Collection of Research Bioresources (JCRB, Japan). 
 
2.2.2 In-vitro cell-based assays 
Short and long term cytotoxic effect of AQHAR was determined by MTT {3-(4, 5- 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (Life Technologies) and colony formation 
assay, respectively. The ROS (Reactive Oxygen Species) and DNA damage were detected using 
fluorescent staining using the Image-iTTM LIVE Green Reactive Oxygen Species Detection Kit 
(Molecular Probes Inc., USA) as per manufacturer’s instructions and described earlier [29]. The 
expression levels of proteins in control and AQHAR treated cells were determined by 
immunoblotting and immunofluorescence assays [29]. Quantitation was performed using the 
Image J software (National Institute of Health). 
 
2.2.3 In vivo assay 
Tumor growth assays were performed using female BALB/c nude mice. Subcutaneous 
xenograft and tail vein- lung metastasis models were used to examine the effect of AQHAR on 
tumor growth and metastasis potential of A549 cells. 
 
2.2.4 Statistical analysis 
All experiments were carried out in triplicates, and data were expressed as mean ± standard 
deviation (SD). Statistical analysis was performed using the SPSS 13.0 software (SPSS Inc., 
Chicago, USA). Differences among samples were evaluated by using analysis of variance 
	11	
	
	
(ANOVA) and Duncan’s multiple comparison method. Significant difference was assumed at 
p<0.05. 
 
2.3 Results and Discussion 
2.3.1 AQHAR selectively inhibited the growth of cancer cells and caused apoptosis at higher 
doses 
Human normal and cancer cells were treated with AQHAR (25 µg/ml) for 48 h. As shown 
in Fig. 2, we found that AQHAR caused toxicity to cancer. Of note, normal cells treated in parallel 
did not show toxicity at equivalent doses. AQHAR inhibited cancer cell multiplication in a dose-
dependent manner, while normal cells remained unaffected. Apoptotic population of cancer cells 
increased significantly with increasing doses of AQHAR compared with the untreated control 
group. The data was evident by examining both cell count and cell morphology observed under the 
microscope, suggesting that AQHAR is selectively toxic to human cancer cells. Cancer cells treated 
with AQHAR also showed inhibition of their long-term multiplication and colony-forming 
efficacy. The data suggested that AQHAR causes death of cancer cells selectively and hence may 
be very useful for cancer therapy [41-44]. In light of this, we set out to determine the mechanism 
of action of AQHAR-cytotoxicity. Molecular analyses on detection of DNA damage and oxidative 
stress revealed that cancer cells treated with AQHAR suffered DNA as well as oxidative damage 
and stresses (Fig. 3). DNA damage was detected by Comet assay wherein the presence of DNA tail 
indicated the DNA damage. Whereas cancer cells showed comet assay-tail, normal cells showed 
no DNA tail after AQHAR treatment. Reactive oxygen species are chemically reactive molecules 
that have interruptive role normal cell structures and functions.  Excessive amount of reactive 
oxygen species may cause irreversible damage to internal cell organelles, proteins and lipids 
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leading to cell death. We elucidated protein expression and found that key cell growth proteins 
were reduced selectively in the cancer cells upon the treatment with AQHAR. Our findings are 
consistent with the other studies wherein these proteins have been identified as anti-cancer targets 
[45-47]. 
 
2.3.2 AQHAR caused tumor-suppression and inhibited lung cancer metastasis in animal model 
Since the anticancer activity in aqueous extract could be extremely beneficial for human 
consumption, we examined its anti-cancer effect in mice model (Fig. 4). We found that the tumor 
growth of untreated mice gradually increased, but AQHAR-treated mice showed 75% suppression 
of tumor growth, with no notable side effects. There was also a marked decrease in blood vessel 
formation and other factors necessary for the tumor growth in the AQHAR-treated mice with a 
large area of tissue degradation in cancer mass. We also investigated the anti-metastasis activity of 
AQHAR in mice lungs. Untreated mice showed big tumors in the lung, whereas AQHAR-treated 
mice showed significant reduction in the number (more than 50%) and volume of lung tumors, 
suggesting that AQHAR possessed a strong anti-metastasis potential. Taken together, we propose 
that AQHAR could be useful as a potent and safe natural anti-cancer medicine. 
 
2.3.3 Comparison of AQHAR and Cucurbitacin B activity 
We next used Cucurbitacin B, a major constituent of AQHAR. We found that Cucurbitacin 
caused comparable cell death in both the cancer and the normal cells. Although the pattern of death 
in the cancer cells was identical to that was caused by AQHAR extract, toxicity in the normal cells 
raised serious questions to conclude the presence of alternate chemicals in the constituency of 
extract that offered protection to the physiological. We tested various types of cancer cells. 
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Osteogenic sarcoma is a highly aggressive and malignant cancer of bone, characterized by 
production of malignant osteoid and rapid metastasis to the rest of the body. Non-small cell lung 
carcinomas are cancer of lung, of various types, varying in aggressiveness and origin. Cervical 
cancer arises in cervix and is characterized by severe and abnormal vaginal bleeding and pelvic 
pain along with the tumor formation and failure of fertility. Breast cancer is characterized by lump 
development, severe pain, aggressiveness, and varying molecular rapport. Colorectal carcinoma is 
the cancer of colon and rectal wall, characterized by extensive swelling, secretions, loose and 
bloody stools, and indigestion. Malignant melanoma is one of the most aggressive forms of skin 
cancer, with a very high recurrence rate. It is characterized by patchy nodule formation, which 
often bleed and pain and spread to internal organs to eventually shut the body completely.  
We tested the potential of Cucurbitacin B against a variety of cancer derived cells and found that 
the toxicity was highly variable and hence optimization of the dose would be required for different 
cancers. In parallel assays, using human normal cells we found that contrary to AQHAR, 
Cucurbitacin B caused toxicity in normal cells as well (Fig. 5). Cytotoxicity of Cucurbitacin B to 
the human living cells has been earlier attributed to disruption internal structures crucial for cell 
division [48, 49].  Direct observation of cells under the microscope and cell cycle analysis 
supported these data.  
 
2.4 Conclusion 
The present study demonstrated anti-cancer activity in the aqueous extract of H. 
angustifolia roots (AQHAR), both at cellular level and animal model. Mechanism of AQHAR as 
evidenced is summarized in Fig. 6. 
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Herbal medicines have been known to enhance the immune function and speed up recovery, 
alleviate radiochemotherapy-related toxicities, improve quality of life, and extend survival, hence 
are popular as complementary treatments [29]. However, the exact mechanism of their activities 
has not been resolved and limits their usage in clinic. We, hereby, report that the aqueous extract 
of AQHAR causes selective toxicity to cancer cells (Fig. 7). The mechanism is through an induction 
of reactive oxygen species and DNA damage, ultimately leading to the cell growth arrest and cell 
death. Of note, normal cells remained unaffected at the equivalent doses. Cucurbitacin B was toxic 
to both cancer and normal cells. The selective cancer cell toxicity was translated in animal model 
by tumor growth suppression and anti-metastasis in mice, without any apparent toxic effect (Fig. 
7). 
AQHAR is proposed as a promising natural and safe anti-cancer reagent for cancer 
treatment, and warrant further studies, to dissect the molecular mechanisms of such multiple 
activities of AQHAR and its chief components such as Cucurbitacin B followed by its possible 
recruitment for effective cancer treatment. 
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Fig. 2. AQHAR was selectively toxic to the U2OS cancer cells at 25 mg/ml dose at standard in 
vitro conditions. 
Li and Garg et al. 2016 PLoS One 11(3): e0152017 
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Fig. 3. AQHAR caused DNA damage and oxidative stress in the cancer cells, which resulted into 
growth arrest and apoptosis via the induction of reactive oxygen species 
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Fig. 4. AQHAR continual treatment in the in vivo balb/c nude mice model caused suppression of 
the growth of subcutaneously placed cancer cell xenograft, and caused inhibition of lung 
metastases. 
Li and Garg et al. 2016 PLoS One 11(3): e0152017 
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Fig. 5. Cytotoxicity of Cucurbitacin B on cancer and normal human cells. Effect of Cucurbitacin 
B on a variety of human cancer and normal cells, ***p<0.001 denotes statistically significant 
difference between the control and treated groups. 
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Li and Garg et al. 2016 PLoS One 11(3): e0152017 
 
Fig. 6. Schematic representation showing the effect of AQHAR on cancer cells by induction of 
oxidative stress (ROS) and DNA-damage leading to activation of growth arrest and apoptosis 
signaling. 
Li and Garg et al. 2016 PLoS One 11(3): e0152017 
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Fig. 7. Summary of selectivity in toxicity caused by AQHAR treatment, but not Cucurbitacin B 
in the cancer cells and normal cells. 
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Chapter 3 
Cucurbitacin B 
 
 
 
 
 
 
 
 
 
	22	
	
	
3.1 Introduction  
Cucurbitacins are chemically characterized by tetracyclic cucurbitane (triterpene 
hydrocarbon) nucleus skeleton 19-(10à9b)-abeo-5a-lanostane base, varied by the positional 
substitution of an oxygen atom (Fig. 8) [50, 51]. There are mainly 40 known species of 
Cucurbitacins and their derivatives, divided into 12 groups namely A, B, C, D, E, I, H, Q, R, 
dihydrocucurbitacin B, etc. [52]. These are usually crystalline in nature, purgative, hydrophobic 
and easily soluble in organic solvents with absorption maxima for ultraviolet light ranging from 
228 to 234 nm, having exceptions such as Cucurbitacin H, which is usually an amorphous solid. 
Various studies have been conducted to the effects of these compounds in various cell lines in vitro 
and in vivo against different cancer subtypes (A/B/E/D/I/Q - lung; B/E/D/I/dihydrocucurbitacin B 
- breast, neurological, colon and hepatocellular; E/I - prostate; E - ovarian; D/dihydrocucurbitacin 
B - leukemia; D - lymphoma; Q - murine). Cucurbitacin B has been one of the most explored for 
its role in biological systems. Cucurbitacin B (C32H46O8, molecular weight 558.712 g/mol, 19-
(10à9β)-abeo-10-lanost-5-ene triterpene), found in the plants of Cucurbitaceae and other plant 
families like Brassicaceae, is classified as a steroid with peculiar bitter taste and cytotoxic 
properties.  Its bitterness could offer it protection against predators and parasites [53]. It has 
previously been known to be effective against various illnesses notably generalized inflammation 
and algesia, carbon chloride-induced hepatotoxicity and profound cholestasis, CD18-mediated 
disorders, infestation of insects, cell adhesion and leukemic disorders, immune mediated and 
angiogenic disorders, etc. [54-56].  Dantas et al. analyzed few derivatives of Cucurbitacin obtained 
from the seeds of Cayaponia racemosa for cytotoxic potential [57].  Nearly all were lethal to brine 
shrimp and inhibited cancer cell proliferation.  However, their toxicity did not reach the order to 
inhibit the biological development of sea urchin or mouse erythrocytic lysis.  The authors credited 
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this to the chemical structure of Cucurbitacins, and postulated that such differences in toxicity 
profile could be attributed to the position of carbonyl group at carbon-11 and absence of a double 
bond between carbon-23 and carbon-24.  In another study, authors isolated a chemical substitute 
of Cucurbitacin B from the fruiting bodies of mushroom Leucopaxillus gentianeus, which differed 
from Cucurbitacin B in lacking an oxygen substituent from at carbon-16, and screened for anti-
tumor toxicity with respect to chemical structure variation [55].  This minute substitution might be 
responsible for its significant (about 6-fold) anti-tumor profile.  It has high affinity for glycosides 
and - not rare to find Cucurbitacin B in a naturally bound form.  Hatam et al. isolated and performed 
NMR studies on Cucurbitacin glycosides derived from the fruit of Citrullus colocynthis L. Schrad 
[58].  Cucurbitacin B showed strong affinity to human serum albumin via hydrophobic and 
electrostatic forces, and increased the binding of ibuprofen to albumin [59].  This indicated the 
catalytic role of Cucurbitacin B in NSAIDs-pharmacokinetics. 
 
3.2 Cucurbitacin B - sources  
Cucurbitacin B has been extracted from plants of various families and genera around the 
world for research purpose.  We examined the effect of Cucurbitacin B, derived from Helicteres 
angustifolia [29], on a variety of cancer and normal cells and discovered its cytotoxic potential in 
bone osteosarcoma cells at nanomolar doses.  Cucurbitacin B fractionated from the methanolic 
extract of Licaniaintra petiolaris was analyzed for toxicity via kenacid acid cytotoxicity assay [60] 
and – caused, at the dose less than 0.01 µg/ml, more than 50% cell death in human oral epidermoid 
carcinoma cells.  Cucurbitacin B obtained in both pure and glycoside form from the fractionation 
from root extract of Casearia arborea showed potent cytotoxicity against glio-sarcoma and 
melanoma cell lines [61]; from the chloroform-methanol extracts of Cucumis prophetarum it 
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showed cytotoxicity against tumor derived and virally transformed mouse cancer cells [62]; from 
the fruiting bodies of the fungal mushroom Leucopaxillus gentianeus it showed very strong 
cytotoxicity against NSCLC, RCC, HCC and HER2-/ER+ breast carcinoma cells [53]; from the 
stems of Cucumis melo it showed significant cytotoxicity against NSCLC and HCC in vitro via 
activation of phospho-STAT3 [63]; from the fruiting bodies of the fungal mushroom Leucopaxillus 
gentianeus it showed cytotoxicity against NSCLC, RCC, HCC and HER2-/ER+ breast carcinoma 
cells [53]; and from the methanol extract of Trichosanthes kirilowii Cucurbitacin B and its close 
relatives demonstrated potent anticancer activities mediated through HIF-1α and NFκB 
suppression [64].  From the air-dried rhizomes of Begonia nantoensis it not only showed 
cytotoxicity against NSCLC, HER2-/ER+ breast carcinoma, gastric adenocarcinoma and non-
neoplastic nasopharyngeal epithelial cell carcinoma cells, but also inhibited HIV replication in 
human T-lymphocytes, flaunting its potential as an anti-viral molecule [65]. 
Many studies have shed light on other medicinal properties of Cucurbitacin B.  Yesilada et 
al. showed potent anti-inflammatory activity in a fraction from the freeze-dried fruit juice of 
squirting cucumber Ecballium elaterium L. Rich [66].  Rawat et al. demonstrated the anti-oxidant 
and anti-inflammatory potential of extracts of cucurbits Lagenaria siceraria, Cucurbita pepo, Luffa 
cylindrical [67].  Overall, in last 50 years, Cucurbitacin B has been shown to possess therapeutic 
value for ailments like cancer, HIV-AIDS, and inflammatory disorders.  Indeed, methods for 
preparing Cucurbitacin with longer shelf life have been developed [68].  More recently, several 
studies, using in vitro and in vivo approaches, have reported its mechanism of action. 
 
3.3 Cucurbitacin B - anticancer activity 
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Many researchers around the world have based their research questions on the activity of 
Cucurbitacin B in cancer cells.  Cucurbitacin B has been shown to possess strong anticancer activity 
in a variety of cancer cell lines in vitro and in vivo (Fig. 9). 
 
3.3.1 Breast cancer 
Tannin-Spitz et al. isolated Cucurbitacin glycosides from the leaves of Citrullus colocynthis 
and found that the combination (Cucurbitacin B/E glycosides 1:1) inhibited the growth of breast 
cancer cells in a dose and time dependent fashion, and forced the cells into G2/M phase cell cycle 
arrest furthering into apoptosis [36].  Growth arrest was elucidated by the downregulation of 
p34Cdc2/cyclin B1 protein complex and upregulation of phospho-STAT3 and p21WAF1.  Breast 
cancer cells treated with the combination of Cucurbitacin B and glycosides showed remarkable 
annular appearance representative of actin filament disruption.  This led to ER status independent 
inhibition of PKB protein phosphorylation and reduction in the expression of Survivin, contributing 
to apoptosis.  Wakimoto et al. confirmed that Cucurbitacin B induced dose dependent disruption 
of actin microtubules and filaments to illustrate rapid morphological changes in breast cancer cells, 
as soon as 15-20 minutes after exposure to the compound [69].  These were due to the disruption 
of F-actin within 3-5 minutes after exposure, followed by disruption of microtubules over 15-20 
minutes.  These findings were verified using nude mice, in which tri-weekly orthotopic 1 mg/kg 
intra-peritoneal injections of Cucurbitacin B resulted in about 50% tumor size growth suppression. 
Duangmano et al. (2010) reported that Cucurbitacin B inhibited the telomerase activity in 
the breast cancer cells [70].  Telomere erosion and telomerase inhibition was supported with the 
inhibition of hTERT and cMYC proteins and consequential cell cycle arrest into G2/M phase [70, 
71]. Two years later they reported downregulation of cyclin B1 (key cell cycle regulatory protein) 
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by Cucurbitacin B [10].  They also showed inhibition of phosphorylation of GSK-3β, resulting in 
enhanced activity of the β-catenin-degradation complex, accompanied with downregulation of 
galectin-3. These results indicated an over obstruction of canonical Wnt/β-catenin signaling axis.  
They also reported the role of neucleophosmin/B23 in breast cancer cells [48].  
Nucleophosmin/B23 protein plays an important role in controlling cellular cycling activities, and 
continuously patrols from nucleolus to cytoplasm and back. Microtubules are cytoskeleton builders 
consisting of α- and β-tubulin subunit chains, and have fundamental role in maintaining cell 
structure, motility, trafficking and division.  Shortage of nucleophosmin/B23 may lead to 
disruption of tubulin subunit polymerization. The authors found that Cucurbitacin B treatment 
caused strong anti-proliferative and apoptotic effects in breast cancer cells through downregulation 
of nucleophosmin/B23 and disruption of microtubule polymerization. They investigated the 
effectiveness of Cucurbitacin B in BRCA1-defective breast cancer cells [72], where it 
counterpoised uncontrolled proliferation and drug resistance of cancer cells.  Additionally, it 
caused up regulation in the expression of cell cycle inhibitors p21WAF1 and p27KIP1, driving the cells 
into apoptosis. 
HER2 status and integrins play a vital role in the carcinogenesis in breast cancer cells. 
HER2/neu, a proto-oncogenic protein, is a mitogenic tyrosine kinase receptor, which directly 
participates in cell transformation, survival and proliferation. Integrins are a large family of 
extracellular matrix (tumor cell microenvironment governing) receptor proteins, composed of two 
a- and two b-glycoprotein units linked with non-covalent bonds. There are about 24 popular 
integrin dimers, distinctly mended by at least 18a and 8b subunits. Integrins ITGAVB3 and 
ITGA6B4 specifically foster survival and cell motility [73-75], whereas ITGB1 and ITGB3 induce 
apoptosis (integrin-mediated cell death) [76].  Gupta and Srivastava (2014) reported that 
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Cucurbitacin B treatment inhibited HER2 receptor and cell adhesion integrins, and triggered 
integrin-mediated cell death via B1 and B3 upregulation through a dose and time dependent BAX 
and caspase 8 cleavage [77, 78].  They also reported that Cucurbitacin B treatment in HER2+ breast 
cancer cells reduced their invasiveness by EMT reversal.  HER2+ cells acquire mesenchymal 
properties via upregulation of TGFβ and downregulation of E-cadherin [79].  Cucurbitacin B 
inhibited the expressions of TGFβ, SMAD, SNAIL, SLUG, ZEB1 and N-cadherin, and abrogated 
the expression of E-cadherin in HER2+ breast cancer cells. Cucurbitacin B treatment induced 
autophagy in breast cancer cells [80].  It caused DNA damage in HER2- breast cancer cells via 
ROS mediated upregulation of γH2AX and phosphorylation of ATM/ATR resulting in p53-
dependent cell apoptosis.  Autophagy induction was confirmed by the appearance of autophagic 
vacuoles in monodansylcadaverine (MDC) staining and upregulation of Beclin1, ULK1 and LC3 
in a time and dose dependent manner.  The effects of ROS reversed if the cells were pretreated 
with NAC.  Cucurbitacin B also reduced the metastatic potential of the breast cancer cells [81].  At 
the non-apoptotic dose, Cucurbitacin B delayed migration and invasion potential of the breast 
cancer and human vascular endothelial cells in a time and dose dependent manner.  It was further 
accompanied by inhibition of angiogenesis potential and a dose dependent suppression of 
VEGF/FAK/MMP9 signaling axis.  These results were validated via retrograde inhibition of FAK 
using its inhibitor FI14 and genetic silencing, and in vivo studies. 
 
3.3.2 Lung cancer 
Lang et al. tested the effect of Cucurbitacin B on NSCLC cells [82].  They showed that the 
highly oxygenated bitter triterpene (Cucurbitacin B) caused moderate to potent cytotoxicity with 
IC50 0.13 µM in 48 h and 0.04 µM in 72 h.  Thiols are one of the crucial redox regulators for 
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cytoskeleton remodeling, cell cycle progression, mitochondrial apoptosis and regulation of redox 
sensitive signal transducers and activators of transcriptors.  Kausar et al. (2013) showed that the 
thiols act as the intermediate between Cucurbitacin B and its toxicity in lung cancer cells [40].  All 
cytotoxic effects were attenuated with thiol anti-oxidant NAC pretreatment, whereas exacerbated 
with GSH synthesis inhibitor BSO.  They demonstrated the physical interaction of Cucurbitacin B 
with NAC and glutathione (GSH) extracellularly using ultraviolet (UV) and FTICR mass 
spectrometry.  Furthermore, Guo et al. reported that Cucurbitacin B in lung cancer cells also caused 
DNA damage via ROS formation, and let cells into G2/M cell cycle arrest [83].  ROS caused double 
strand DNA breaks, which led to ATM-mediated activation of Chk1-Cdc25C-Cdk1 and p53-14-3-
3-σ-CDC-25C-CDK1 pathways leading to mitotic interruption in parallel. Lung cancer when 
treated with Cucurbitacin B inhibited phosphorylation of STAT3 to cause growth arrest and 
apoptosis in dose and time dependent manner [84]. It inhibited STAT3 pathway leading to 
downregulation of cyclin B1 and BCL2.  Shukla et al. (2015) reported global DNA methylation-
associated epigenetic modifications due to Cucurbitacin B treatment in highly aggressive NSCLC 
cells [85].  They reported that the altered histone modifications at the respective promoter sites 
caused upregulation of p16INK4Aand p21WAF1 and downregulation of hTERT to cause replicative 
senescence, growth arrest, and apoptosis.  They also found that Cucurbitacin B caused 
downregulation of cMYC/kRAS at only protein and not transcriptional level.  5-mC reduction was 
accompanied with downregulation of DNMTs, HDACs and SIRT, and upregulation of CBP and 
PCAF.   The results were validated using carcinogen NNK-induced lung tumorigenesis in mice, 
advocating epigenetic modulation to be a significant anticancer mechanism of Cucurbitacin B. 
Silva et al. (2016) reported PI3Kinase and MAPK pathway inhibition due to Cucurbitacin 
B treatment [86].  The treatment delayed cell migration, alleviated invasion potential, and caused 
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dose and time-dependent apoptosis. It inhibited MMP release and FAK activation, and upregulated 
(activated) phospho-AKT, -ERK, -JNK and -NFκBp65. In another study, Cucurbitacin B exhibited 
a strong anti-metastatic potential in the NSCLC cells via down regulation of canonical Wnt/β-
catenin signaling axis [87].  In both moderately aggressive and highly aggressive NSCLC cell lines 
in vitro, Cucurbitacin B treatment delayed migration and impeded invasion with downregulation 
of Wnt3/Wnt3α, FZD7, β-catenin, MMP2, cMYC, cyclin D1, Survivin and VEGF and upregulation 
of E-cadherin proteins.  It also showed potent anti-angiogenic effects.  These effects regressed upon 
the treatment with EMT inducer TGFβ or by retrograde genetic knockdown of Wnt3/Wnt3α.  All 
the results were validated using NNK-induced lung tumorigenesis in mice. Intraperitoneal 
injections of Cucurbitacin B at 0.1 mg/kg body weight, administered thrice a week, reduced the 
tumor incidence, frequency, and volume by 80-90% compared to vehicle group. 
3.3.3 Skin cancer 
In malignant melanoma, Cucurbitacin B inhibited cell proliferation as well as their 
migratory potential [88]. Treatment in a mouse melanoma cell line caused cell membrane bleb and 
deformation, and multiploidy, via ROS induction resulting in dose dependent G2/M phase growth 
arrest.  There was significant depletion and aggregation of G-actin protein from the cellular 
cytoskeleton, and were reversed using NAC. NAC is a N-acetyl derivative of L-cysteine, and an 
established potent antioxidant.  Inhibition of growth of subcutaneously implanted melanoma cells 
was validated using female C57BL/6 mice. Cofilin is an actin-depolymerization factor. It is 
regulated by phosphatidylinositol phosphate, pH variations, redox balance, and competition with 
tropomyosins [89], activated by dephosphorylation at its serine residue 3 by chronotropin or 
slingshot phosphatases, and inactivated by phosphorylation via LIM or TES kinases [90].  Rho-
associated kinases indirectly modulate the stress fibers and focal adhesions [91].  Cofilin and actin 
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form rods and are implicated in the pathogenesis of neurogenerative disorders [92].  Cucurbitacin 
B dramatically activated cofilin via thiol oxidation, which formed rod like structures co-localizing 
with the actin (tandem rods) in melanoma cells [93].  Rho kinase and LIMK were downregulated, 
which were reversed by the treatment of thiol-ROS-scavenger NAC.  Cucurbitacin B induced 
slingshot homolog-1 dependent hyper activation of cofilin and formation of cofilin-actin rods 
downstream of actin aggregation.  VASP, an F-actin barbed end binding protein facilitates actin 
filament elongation through interaction with G-actin, profilin and other actin regulatory factors 
[94]. It directly controls the assembly of the actin-filament mesh, transforms the morphology and 
behavior of membrane protrusion structures, and also contributes in cell migration and adhesion. 
Cucurbitacin B induced VASP phosphorylation (deactivation) at serine 157 [95].  It was mediated 
by cAMP independent activation of Gα13/RhoA/PKA pathway, to generate VASP clumps.  These 
clumps co-localized with amorphous actin aggregates, prior to the formation of highly ordered 
cofilin-actin rods in melanoma cells. 
 
3.3.4 Brain cancer 
Cucurbitacin B inhibited growth of human glioblastoma multiforme cells by intense 
disturbance in its internal cytoskeleton [96]. Within 15 to 30 min of treatment, it caused loss of 
pseudopodia, multi-nucleation and skirting up of cells associated with disruption of actin and 
microtubules, but was followed by the activation of cell survival pathways.  It also inhibited cell 
proliferation, decreased migration, and caused cell cycle arrest in G2/M phase and apoptosis.  After 
30 minutes of treatment, it caused upregulation of phospho-p38, JNK, JUN and ERK in a time-
dependent manner. This was validated using SP600125, a broad-spectrum anthrapyrazolone 
inhibitor of JNK.  SP600125 blocked the effects of Cucurbitacin B. The treated glioblastoma 
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multiforme cells exhibited marked disintegration and rearrangement of filamentous actin and β-
tubulin. Touihri-Barakati et al. recently found that the proliferation, adhesion and migration 
inhibition due to Cucurbitacin B may be mediated through α5β1 integrins [38].  Laminins and 
fibronectin are extracellularly present high molecular weight cell adhesion proteins, and constitute 
major component of basal lamina contributing to cell adherence, dissemination and differentiation.  
Their upregulation is commonly found in EMT. Authors found significant downregulation of 
Laminin-1 and fibronectin in human glioblastoma cells. Further introspection in microvasculature 
endothelial cells demonstrated potent anti-angiogenic activity.  Cucurbitacin B also showed 
remarkable anticancer effects in human neuroblastoma cancer cell lines [97].  It induced G2/M 
arrest and apoptosis supported with upregulation of p53, p21 and BAX, and down regulation of 
BCL2. This was accompanied with the down regulation of proteins (CDK1 and Cyclin B1) 
essential for cell cycle progression.  It also inhibited JAK2/STAT3 signaling cascades and induced 
JNK/p38MAPK-activation/ERK-inactivation. Shang et al. reported that PTEN activation is crucial 
and adds positively to the anti-proliferative effects of Cucurbitacin B [98]. Apart from proliferation 
inhibition, cell cycle restraining and apoptotic trend, they dissected the possible mechanism of 
inhibition of AKT signaling pathway in human neuroblastoma cells. Although they found that some 
of the key down-stream factors in the pathway viz., NFκB, AMPK and p38 did not alter; genetically 
activating AKT using plasmid vector carrying myr-AKT locus revered the toxic effects of 
Cucurbitacin B.  Silencing of activated PTEN resulted in AKT phosphorylation and upregulation 
of the proapoptotic markers and repression of cyclins. 
 
3.3.5 Liver cancer 
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Dat et al. (2010) isolated Cucurbitacin B and its close relatives, which demonstrated potent 
anticancer activities mediated through HIF-1α and NFκB inhibition in hepatic carcinoma cells [64].  
Cucurbitacin B inhibited the activation of HIF-1α in an artificially induced hypoxia cell-based 
reporter assay, and inhibited NFκB in secreted alkaline phosphatase reporter assay. VEGF-specific 
ELISA validated its anti-angiogenic potential.  Chan et al. (2010) explored the activity of 
Cucurbitacin B in human hepatocellular carcinoma in vitro and in vivo, where they reported that it 
caused dose and time dependent clonogenic inhibition via STAT3 independent S-phase arrest [99].  
This phenomenon occurred probably via ERK1/2 activation and suppression of Cyclin D1, CDC2, 
and c-RAF phosphorylation.  Cucurbitacin B induced ROS-mediated DNA damage leading to 
apoptosis and autophagy in hepatocellular carcinoma cells [100]. It was supported with increased 
upregulation of γH2AX, phosphorylation of ATM/ATR and CHK1/CHK2, modulations in BCL2 
family proteins and cleavage of caspases-7 and -9). They also ascertained Cucurbitacin B-induced 
autophagy, which was marked by vacuolization, upregulation of LC3II and ULK1, downregulation 
of AKT and mTOR proteins and activation of PTEN. They dissected that the contemporary 
activation of PTEN protein, which probably led to AKT/mTOR inhibition, had indirect correlation 
with autophagy. They used silencing RNA to genetically knockdown PTEN gene to confirm 
inhibition of AKT and upregulation of autophagy specific proteins. 
 
3.3.6 Blood cancer 
Cucurbitacin B with variable IC50 value induced cell cycle arrest and cellular differentiation 
in acute promyelocytic and myeloid leukemia [101]. It induced S phase growth arrest, swollen 
morphology of cells, altered cytoskeleton due to rapid and haphazard polymerization of 
filamentous actin into globular aggregates, and decreased clonogenicity in the immature blasts.  It 
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also caused upregulation of monocytic-/granulocytic- specific CD11b, signifying cell 
differentiation. Cucurbitacin B suppressed the activated MAPK/ERK pathway and inhibited 
STAT3 activation in various human chronic myeloid leukemia cells [102].  Protein expression 
analysis showed activation of STAT3, RAF, MEK and ERK proteins is inhibited. STAT3 
activation modulation ensued through a crosstalk mechanism, which also resulted into G2/M arrest 
and apoptosis.  Similar findings were noted in human leukemic Jurkat cells [101].  Cucurbitacin B 
caused cofilin dephosphorylation and actin dynamics intrusion, prompting into cell volume 
increase and simultaneous multi-nucleation.  It also induced autophagosomes and LC3II 
upregulation as a compensatory protective response.  Constitutive suppression of autophagy led to 
dramatic increase in caspase-3 mediated autophagy. 
3.3.7 Others 
Gao et al. (2014) reported the anticancer effects of Cucurbitacin B in prostate cancer cells 
[103]. Cucurbitacin B caused selective toxicity human epithelial type prostate cancer cells. ACLY 
is an enzyme, which metabolically converts mitochondrial citrate into acetyl coenzyme A [104, 
105]. Acetyl coenzyme A is a major precursor and constituent responsible for synthesis of fatty 
acids and mevalonate, which promote carcinogenesis. Cucurbitacin B downregulated the 
expression of acetyl coenzyme A, fatty acid synthesis and mevalonate, supplemented with 
mitochondrial ROS production. It was suggested that the inhibition of the acetyl coenzyme A 
signaling might be one of the downstream mechanisms of ROS-mediated intracellular insults 
leading into apoptosis.  Cucurbitacin B exhibited significant toxicity in human laryngeal cancer 
cells leading to G2/M phase arrest [37, 106, 107]. This was supported with downregulation of cyclin 
B1, phospho-STAT3 and BCL2, associated with chromatin condensation, nuclear fragmentation, 
and appearance of apoptotic bodies in a dose and time dependent manner.  Cucurbitacin B inhibited 
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proliferation and induced G0/G1 cell cycle arrest in a dose and time dependent manner in gastric 
cancer cells [108].  It suppressed the expression of cyclin D1, cyclin E, CDK4 and CDK2, and 
upregulated the expression of p27, all of which are indicated in inhibition of cell cycle progression. 
It also inhibited phosphorylation of JAK2 and STAT3, and caused apoptosis.  It also induced 
caspase dependent apoptosis and autophagy in SGC7901/DDP DDP-resistant gastric cancer cells 
[109]. It suppressed cell proliferation and induced apoptosis and autophagy via inhibition of 
activation of CIP2A-PP2A-mTORC1 axis. Cucurbitacin B was shown to cause cytotoxicity to a 
variety of bone cancer and normal cells at nanomolar doses [29]. It forced osteoblastoma and 
normal lung fibroblasts into G2/M phase growth arrest, and unanimously activated p53 and pRB 
tumor suppressor pathways, leading to characteristic senescence like growth arrest and/or 
apoptosis.  At 20-100 µM dose it suppressed cell proliferation and induced apoptosis in U-2OS 
human osteosarcoma cells [110].  It inhibited JAK2/STAT3 and MAPK pathways leading to BH3 
domain and caspase family protein modulation to induce cell cycle arrest, along with MMP2, 
MMP9, VEGF inhibition adding up to delay in migration potential of the cells and angiogenesis 
inhibition.  Cucurbitacin B showed anticancer activity in paclitaxel-resistant A2780/Taxol ovarian 
cancer cells [111]. It caused growth inhibition in G2/M phase and apoptosis via upregulation of p53 
and p21, downregulation of BCL2, activation of caspase 3, and suppression of P-gp, suggesting 
potential role against multidrug resistance clinical cancer.  Ma et al. (2014) monitored hypoxia-
induced signaling and modulation by Cucurbitacin B in various cell lines in vitro [112]. They found 
that the activation of HIF-1α-monomer was suppressed due to Cucurbitacin B treatment in a dose 
dependent manner.  They also found that this effect co-existed and correlated with strong 
dephosphorylation of mTOR, p70S6K, 4EBP1, and ERK1/2 proteins.  It also downregulated the 
HIF-1 targets, VEGF and erythropoietin. Contemporary treatment with a known proteasomal 
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inhibitor MG-132 overshadowed the hypoxia signaling suppression, implying that Cucurbitacin B 
did not affect transcriptional coding, but regressed its ubiquitin-mediated proteasomal degradation.  
It also altered microtubule structures in human cervical cancer HeLa and osteosarcoma U-2OS 
cells [113]. It affected mitotic spindles and induced G2/M cell cycle arrest.  Zhang et al. (2012) 
showed that Cucurbitacin B induced caspase-independent autophagy reflux in a variety of cell lines 
[114]. It suppressed cell growth and proliferation, and inhibited interleukin-6 mediated 
phosphorylation of STAT3 in a dose dependent manner.  Increase in mitochondrial-derived ROS 
and activated ERK1/2 and JNK proteins were also observed. It induced autophagy as evidenced by 
appearance of autophagosomes and upregulation of lipidated LC3 II. However, inhibition or 
knockdown of ATG5 and Beclin1 proteins did not rescue the cells from death.  Instead, it forced 
cells to undergo caspase-dependent apoptosis, suggesting a competitive cross relation between 
autophagy and apoptosis. 
 
3.4 Cucurbitacin B - as combination therapy 
Cucurbitacin B and its derivatives have shown synergism with other anticancer agents.  
Marostica et al. (2015) presented DACE, a novel semisynthetic derivative of Cucurbitacin B and 
tested its effect in NSCLC cells as individually and in combination with either cisplatin (9 µM), 
irinotecan (4.25 µM), or paclitaxel (0.125 µM) [115, 116]. Cucurbitacin B (20 mg) was made to 
react with p-toluenesulfonyl chloride (34 mg) and DABCO (20 mg) in dichloromethane (200 µl) 
to obtain tosylated intermediate (20 mg), which was then made to undergo nucleophilic substitution 
using sodium azide (18.2 mg) in dimethylformamide (250 µl) to finally attain DACE. Cisplatin, an 
inorganic water-soluble platinum complex, reacts with and alters DNA after undergoing hydrolysis 
to produce crosslinks.  Crosslinks impair DNA replication, and forces the cells into G2 phase arrest. 
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Irinotecan is a topoisomerase inhibitor. Paclitaxel is a cyclodecane isolated from the bark of Taxus 
brevifolia. It stabilizes microtubules when they are in polymerized form, which causes cell death.  
In combination with either one of three accomplices, DACE (0.125 µM) reduced the risk of drug 
resistance, which is one of the major hurdles today in anticancer therapy by synthetic agents.  It 
also showed selective toxicity to the cancer cells, forced them into G2/M phase cell cycle arrest via 
STAT3 activation suppression and AKT downregulation, filamentous actin aggregation, nuclear 
fragmentation, inactivated cofilin1 suppression and E-cadherin substantiation. DACE also 
interfered with the activation of EGFR and its downstream factors AKT, ERK, STAT3 and 
survivin, contributing to growth arrest and caspase 3-mediated apoptosis.  Efficacy in combination 
with cisplatin has also been checked in cutaneous squamous cell carcinoma [117].  Cucurbitacin B 
(0.1-2.5 µM) with cisplatin (5-20 µM) was pulse exposed to the cells i.e., exposed for a limited 
duration followed by culture in usual growth medium. The combination synergistically 
downregulated cyclin B1 and CDC2 expressions, with reduction in migratory and invasive 
potential of the cells.  In laryngeal squamous cell carcinoma, the combination (0.1 µM Cucurbitacin 
B, 10 µM cisplatin) interdependently suppressed activation of STAT3 and translational expression 
of cyclin B1 and BCL2 [106].  In ovarian cancer, Cucurbitacin B sensitized cells to cisplatin (El-
Senduny et al. 2016). Cucurbitacin B (2 µM) pretreated with cisplatin (10 µM) resulted in enhanced 
cytotoxicity than that by cisplatin alone in both cisplatin sensitive and insensitive ovarian cancer 
cells, via depletion of glutathione and increase in ROS production. It downregulated Dyrk1B, 
phosphorylated ERK1/2 and STAT3, and cyclin B1, leading to G2/M phase growth arrest.  It also 
downregulated BCL2 and APAF1, and upregulated caspase 9 - indicating apoptotic induction.  
These effects afforded by the combination had Cucurbitacin B at the dose of just a fourth of its 
IC50. Cucurbitacin B (1 mg/kg) in combination with paclitaxel (10 mg/kg) injected intravenously 
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suppressed tumor growth in Balb/c nude mice [118].  Treatment was well tolerated by the animals 
and no evident damage in liver and kidneys was observed. 
Docetaxel is a microtubule inhibitor. It prevents formation of microtubules leading to 
failure of growth and cell division.  Gemcitabine, a nucleoside metabolic inhibitor, prevents the 
synthesis of genetic element, hence preventing DNA replication. Cucurbitacin B (0.001-0.05 µM) 
synergistically enhanced the anti-proliferative and apoptosis effects of docetaxel (0.001-0.005 µM) 
or gemcitabine (0.001-0.1 µM) in breast cancer cells in vitro and in vivo, at much low dose of either 
drugs than that are used in chemotherapy, indicating minimum adverse effects [119].  However, 
even with combination, but at only high dose, myelosuppression, hepatotoxicity and leukopenia 
with gemcitabine combination was encountered. In another study, combination of Cucurbitacin B 
(1 µM) and docetaxel (0.025 µM) caused cell cycle arrest at G2/M phase and apoptosis via 
synergistic suppression of phospho-STAT3, BCL2, and Cyclin B1 in laryngeal cancer cells [37, 
107]. Thoennissen et al. reported synergism of Cucurbitacin B with gemcitabine in pancreatic 
cancer [120]. Cucurbitacin B (0.01-0.1 µM) and gemcitabine (0.001-0.01 µM) combination caused 
dose-dependent multi-nucleation, G2/M arrest and apoptosis, associated with inhibition of activated 
JAK2, STAT 3/5, Cyclin A/B1, and BCL-XL, and activation of p21WAF1 and Caspases, more than 
Cucurbitacin B (0.05-0.2 µM) alone.  Same group in another study in 2010 showed that this 
combination also inhibited BCL2 and cMYC adding up to apoptosis in pancreatic cancer cells in 
vitro.  These effects were positively validated in vivo with only mild toxicity [121]. Protein kinase 
activity is crucial for a majority of intra-cellular signaling pathways.  Prevention of protein kinase 
results into cell growth arrest.  Gefitinib is a protein kinase inhibitor and known to be orally active 
selective inhibitor of EGFR, which inhibits autophosphorylation of intracellular tyrosine residues. 
Cucurbitacin B at safe dose (0.5 µM) offered synergistic anti-proliferative affects to benign dose 
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of gefitinib (10 µM) in human colorectal cancer cells in vitro [122], as validated via LDH assay.  
There was more significant down regulation of BCL2, Cyclin D1, and phospho-EGFR and STAT3, 
and upregulation of BAX, BAK and p27KIP1, indicating stronger growth arrest and apoptotic 
signaling.  Thymidylate is one of the important building blocks of DNA. Its synthesis is mainly 
stimulated by tetrahydrofolate.  Methotrexate, an antineoplastic antimetabolite with 
immunosuppressant properties, is an inhibitor of tetrahydrofolate dehydrogenase. Cucurbitacin B 
(0.07 µM) and methotrexate (0.05 µM) combination caused G2/M growth arrest and apoptosis in 
human osteosarcoma cells [39]. This was corroborated by inhibition of protein expression of ERK, 
AKT, and mTOR in JAK/STAT inactive cells.  Further in vivo validation exhibited tumor 
suppression by combination (Cucurbitacin B 0.5 mg/kg body weight, methotrexate 150 mg/kg body 
weight) by 60-80%, which held at 66% after methotrexate withdrawal.  Doxorubicin, a 
topoisomerase inhibiting anthracycline, intercalates DNA and exerts its anticancer activity by the 
suppression of DNA polymerase, topoisomerase II, and methyltransferase [123]. Doxorubicin 
resistant cells are known to entail survivin super-expression [124]. Cucurbitacin B (0.2-1 µM) and 
doxorubicin (1-5 µM) showed synergism against the progression of anaplastic thyroid cancer [125].  
They synergistically enhanced ROS production, with consequential upregulation of cleaved PARP, 
COX2 and phospho-ERK1/2, and downregulation of BCL2, survivin, and JAK/STAT-signaling 
axis.  In a recent study, Cucurbitacin B (up to 0.2 µM) with doxorubicin (up to 0.2 µM) showed 
synergistic anti-tumor activity via inhibition of aurora A leading to G2/M phase cell cycle arrest, 
and IL10-induced STAT3 phosphorylation inhibition [126]. It also induced cofilin 
dephosphorylation and caspase-mediated apoptosis.  
Valproic acid, popular anti-convulsion and mood stabilizing fatty acid, is inhibited by 
histone deacetylase (drug resistance).  Histone deacetylase activates tumor suppressors p53, p21 
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and CDKs, and increase histone acetylation, which suppress the activation of many protoncogenes 
[127].  Cucurbitacin B caused dose dependent toxicity in mouse melanoma cells, followed by 
multiploidy, autophagy and BCL2 upregulation for cell survival [128]. This demonstrated the 
prosurvival role of autophagy in cancer cells after treatment with Cucurbitacin B (1 µM).  When 
administered in combination with valproic acid (1-5 mM), it showed synergism to sensitize the 
cells to the toxicity due to valproic acid. It henceforth caused cell apoptosis and tapered 
multiploidization. Curcumin, obtained mainly from Curcuma longa, a yellow-orange 
phytopolyphenolic pigment commonly known as turmeric, is known for its medicinal properties 
such as anti-oxidant (prevention of ROS production), anti-inflammatory (COX inhibition), and 
anticancer (suppression of protein kinase C).  It showed potency against alcoholic liver injury and 
insult due to lipopolysaccharide, D-(+)-galactosamine and heavy metals [129-131]. It 
fundamentally operates via mitochondrial invasion and is relatively safe to the healthy tissue [132].  
Combination of Cucurbitacin B (143.2 µM) and curcumin (108.6 µM) showed synergism dose and 
time dependently against the human hepatocellular carcinoma [35], forcing the cells into G0/G1 
phase arrest and apoptosis.  It decreased the sensitivity of the cells to p-glycoprotein and reversed 
the resistance to 5-fluorouracil, indicating reversal of multidrug resistance. In vivo validation using 
Cucurbitacin B (10 mg/kg body weight) and curcumin (5 mg/kg body weight) combination resulted 
in greater suppression in tumor growth than with either molecule alone, with enhanced caspase 3 
activity and reduced ATP contents. Cucurbitain B in combination with glycosides exhibited 
excellent antioxidant properties in a dose dependent manner [36, 133]. The combination inhibited 
hydroxyl radical-dependent DEPMPO-hydroxyl radical adduct formation, superoxide radical 
anion-dependent DEPMPO-hydroxyl radical addict formation and singlet oxygen-dependent 
TEMP-singlet oxygen addict generated in the photoradiation-porphin system.  Duangmano et al. 
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(2012) reported that Cucurbitacin B increased the sensitivity of HER2 negative breast cancer 
variants to radiotherapy [49], and caused dose dependent G2/M phase arrest and apoptosis in vitro 
via progressive up regulation of the p21 mRNA.  Further augmentation with radiation resulted into 
rapid cell death. Cucurbitacins - Picracin and deacetylpicrscin from Picrorhiza scrophulariiflora 
inhibited mitogen-induced T cell proliferation and IL-2 [134]. Authors regarded picracin as more 
active in inducing apoptosis of non-stimulated T cells than the other. 
 
3.5 Cucurbitacin B - other biological systems 
Potential of Cucurbitacin B against cardiac, liver, lung, neuronal and skin injuries, systemic 
infections, inflammation, sex-related behavior and adipocyte differentiation has also been 
explored.  Cucurbitacins exhibit a broad range of pharmacological properties such as anti-
inflammatory, antioxidant, antiviral, antipyretic, analgesic and anti-malarial [54, 135, 136]. 
Cucurbitacin B (0.2 mg/kg) offered protection against pressure-overload cardiac hypertrophy with 
potent anti-hypertrophy and anti-fibrosis [137]. Male C57/BL6 mice were undertaken surgical 
aortic banding to induce cardiac hypertrophy.  Cucurbitacin B fed mice demonstrated a significant 
reduction in heart weight, myocardial cell cross sectional area and interstitial fibrosis, etc. These 
effects were further accompanied with inhibition of hypertrophy in phenylephrine stimulated 
cardiomyocytes attributed to inhibition of AKT/mTOR/FOX03A axis and autophagy.  
Cucurbitacin B may be indicated in sepsis-induced acute lung injury (ALI) [138]. A rat ALI model 
following abdominal septic puncture was treated with Cucurbitacin B intraperitoneally.  
Cucurbitacin B-treated rats showed an increase in arterial oxygen partial pressure, and reduction in 
lung effusion, protein content, neutrophils and lymphocytes, and cytokines in a dose dependent 
manner, with 3-5-fold increment in survival.  Histological examination revealed that the pulmonary 
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destruction alleviated with Cucurbitacin B treatment, endorsing its anti-oxidant and anti-
inflammatory properties. Cucurbitacin B offered hepatoprotective and anti-inflammatory effects in 
artificially induced acute liver damage in outbred albino male Wistar rats [139].  Flower-squeezed-
sterile-juice of Cucurbitacin B administered orally at 200-700 µL/kg body weight for three days 
before artificial induction of carbon chloride mediated hepatotoxicity resulted into mild and 
reversible damage in the liver parenchyma and liver function tests.  However, higher dose showed 
signs of irreversible hepatotoxicity.  Psoriasis is a chronic keratinocyte inflammatory adaptive 
immune-mediated disease, involving Th1-type immune cells and cytokines, encompassing about 
0.5 to 3% human population globally. It is characterized by hyperproliferation, inflammation and 
abnormal keratinocyte differentiation.  Keratinocytes act as the first line barrier in immune 
surveillance, and govern innate immunity via inflammation-associated molecules like NFκB. 
Imiquimod is an analog of adenosine, a chemical stress inducer.  Topical application of 
Cucurbitacin B inhibited imiquimod-induced pathogenesis of psoriatic dermatitis [140]. It caused 
growth inhibition of keratinocytes, which was mediated by inhibition of NFκB and STAT3 
signaling leading to reduced expression of psoriatic IL8 and CCL20 cytokines, thus reducing 
epidermal hyperplasia and psoriatic pathogenesis.  Yesilada et al. (1988) indexed anti-
inflammatory property of Cucurbitacin B using Whittle method, using a fraction from the freeze-
dried fruit juice of squirting cucumber Ecballium elaterium [66].  They estimated dye leakage from 
the vascular tissue in orally fed the mice.  Vascular leakage corresponded to permeability and 
inflammatory response.  Authors recorded an increase in permeability with Cucurbitacin B dose; 
however, 400 mg/kg body weight (highest) also imposed severe toxicity to the animals. 
Likewise, the ameliorative anti-oxidant effects of Cucurbitacin B and its relatives were 
shown as beneficial against the neuronal injury [141]. It significantly inhibited neuroinflammatory 
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mediators in TLR2/4 agonist-stimulated microglia. Excess TLR activated cytokine and 
complement proteins may result into neuronal injury and consequentially cell death, mediated 
through pro-inflammatory cytokines (TNFα and IL1β/6), and JAK/STAT and NFκB pathways.  
Pretreatment with Cucurbitacin B suppressed the phosphorylation of JAK1, STAT1 and STAT3, 
NFκB transactivation and cytokines’ release, resulting into attenuation of expression of iNOS and 
COX2. It enhanced the activity of Nrf2/ARE pathway to upregulate HO1 and NQO1, and inhibited 
caspase activity to offer significant neuroprotection.  Rawat et al. also evaluated the anti-oxidant 
and anti-inflammatory potential of Cucurbitacin B containing plant extracts [67]. Extracts of 
cucurbits from L. siceraria, C. pepo and L. cylindrical by means of superoxide radical scavenging 
activity assay and catalase activity assay in the presence of xylene orange and Amplex® Red 
demonstrated potent radical scavenging activity.  They also inhibited inflammation specific 
cytokines COX-1 and COX-2 in lipopolysaccharide-induced mice serum.  Cucurbitacin B with 
Cucurbitacin E in the dichloromethanolic extract from the roots of Wilbrandia ebracteata Cogn. 
protected against inflammation and algesia in rats [142].  Male Wistar rats were injected with 
inflammatory agent carrageenan in paws, which developed into inflammation. Inflammation was 
relatively and significantly less in rats fed with the extract.  Furthermore, pain felt with acetic acid 
application in the inflamed area was significantly faint as compared to the vehicle group. 
Cucurbitacin B reduced the likelihood of onset of hepatocellular carcinoma by preventing 
STAT3 phosphorylation and consequent adipocyte accumulation [143].  Phospho-STAT3 
stimulates the regulation of pro-proliferative cyclin D1 and adipogenesis markers PPARγ, aP2, 
C/EBPα, adiponectin and CD36 proteins, and inhibits adipocyte differentiation inhibitor KLF5.  
Seo et al. (2014) showed that Cucurbitacin B suppressed the activation of STAT3, henceforth 
suppressing adipocyte differentiation and accumulation.  Prevention of adipogenesis and lipid 
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accumulation by 0.2-0.3 µM Cucurbitacin B was more promising than by 20 µM resveratrol 
(standardized anti-adipogenic compound).  Genetic silencing of STAT3 significantly attenuated 
the anti-adipogenic activity.  Cucurbitacin B showed synergistic antibacterial and antiviral potential 
against Staphylococcus aureus and Herpes simplex virus -1 [144].  Within a range of dose, 
Cucurbitacin B in synergism with other antibiotics such as tetracycline and oxacillin inhibited the 
growth of clinical drug resistant variant of Staphylococcus aureus, as determined by microdilution 
method and checkboard assay. By means of plaque number reduction assay, it showed potent anti-
HSV-1 potential, comparable to acyclovir.  Cucurbitacin B treatment, however, led to decline in 
the sexual hormone and behavior in male moth Agrotis ipsilon [145].  Cucurbitacin B as an 
antagonist of 20E/EcR/USP complex and signaling pathway staging crucial for sexual behavior 
from the male antennal lobe reduced the amount of AipsEcR and AipsUSP in a dose dependent 
manner, which inhibited central pheromone processing in the adult sexually mature male moth. 
 
3.6 Toxicity 
Cucurbitacin B to the best of our knowledge has not been included in toxic or restricted use 
by any of the drug and safety bureau across the world, nor there is any report claiming its toxic role 
in vivo across the world [146], except an FDA report from 1955 and follow-up in 1983, where the 
authors reported that the median lethal dose of Cucurbitacin B via intraperitoneal route was about 
1 mg/kg in male albino mice at the end of three doses [147]. Cause of death was acute pulmonary 
edema and respiratory arrest.  Smit in 2000 reported that in rabbits the median lethal dose of 
Cucurbitacin B was 0.5 mg/kg body weight after intravenous administration [134, 148].  Ferguson 
et al. also reported of poisoning after human consumption of 700 grams of commercially produced 
Cucurbita pepo L. within 6 h period [149]. Toxic symptoms included bitter taste in mouth, 
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abdominal cramps, diarrhea, and occasional vertigo and syncope. Australian Therapeutic Goods 
Administration has listed Cucurbitacin B free from restricted use and encourages its use in 
combination with other agents [150]. 
Cucurbitacin B in its pure form had median lethal dose of about 5 mg/kg (oral route) [151] 
and 1 mg/kg (intraperitoneal) [147] mice, 0.5 mg/kg (intravenous) [152] in rabbit, and 0.32 mg/kg 
(intravenous) [153] in cat, recorded so far.  Deaths at this dose were accompanied with symptoms 
such as pulmonary edema, however, with no mentioned additional symptoms.  Furthermore, severe 
toxicity leading to death following oral administration were reported in various studies reporting 
the use of plant and extracts - Ecballium elaterium in rabbits caused nervousness, restlessness, 
seizures, anorexia, tachycardia, tachypnea, dyspnea, cyanosis, and diarrhea eventually leading to 
death [154, 155]; Cucurbita texana in Swiss Webster mice caused severe anemia followed by death 
[156]; Citrullus colosynthis and Lagenaria siceraria in goats caused restlessness, anorexia, 
diarrhea, dehydration, anemia, dyspnea, kinetic latency, internal hemorrhages, pulmonary 
emphysema, enteritis, multi-organ failure, and eventually death [157]; and Citrullus colocythis in 
Bovans-type chicks led to hepatic fatty changes and toxicity, catarrhal enteritis, pulmonary 
emphysema, renal tubular necrosis, but these symptoms reversed after 4 weeks of withdrawal 
[158]. 
Various human toxicity complaints have been reported from around the world after 
accidental or intentional consumption of fruit juice or zucchini squash [154, 159, 160].  Symptoms 
reported were similar to those in the in vivo studies pivoting digestive and neurological systems.  
However, following topical application with the same extract the human subjects remained 
asymptomatic [161].  Since the median lethal dose via oral route was significantly higher that the 
parenteral - possibly digestion, emergence of metabolites and their absorption from the gut before 
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reaching systemic circulation is crucial to alleviate its toxic effects and liberate its medicinal 
potency.  Moreover, the oral feeding led toxicities and deaths involved components additional to 
the Cucurbitacin B, advocating bail for Cucurbitacin B off severely toxic profile.  Therefore, oral 
administration of purified form of Cucurbitacin B as an independent executor may be justified, as 
long as the dosage is conscientiously tailored and the symptoms are cautiously checked. 
 
3.7 Cucurbitacin B - Biological supply chain and future scope 
The natural origin and synthetic production of Cucurbitacin B have been extensively 
studied over the last few decades.  Jung and Lui (2010) presented the artificial convergent edifice 
efforts [162]. Razavilar and Choi (2014) found that the diffusivity of Cucurbitacin B depends on 
wiggling motion of the block copolymers to diffuse while the contemporaneous water molecules 
diffused via a hopping mechanism [163]. Toker et al. (2003) proposed a novel method to naturally 
increase the yield of Cucurbitacin B using Ecballium elaterium callus culture technique [164]. They 
showed that the subculture calluses of stem explants incubated in medium supplemented with 1 
mg/l benzyl adenine and 0.1 mg/l naphthalene acetic acid could competently accrue the compound. 
Mei et al. (2016) suggested a process for Cucurbitacin B bioproduction from one of its parent 
glycoside using a specific Streptomyces sp. [165], using enzyme broth incubation and extraction 
ethyl acetate. The process was mild, simple and prolific; nevertheless, its hydrophobic and 
electrostatic structure left it prognostically difficult.  Quick exploitation followed by attenuated 
performance of Cucurbitacin B may abet solid doubts about the treatment modality and dosage in 
practical use. Cucurbitacin B is hydrophobic, hence suffers in situ absorption.  Its absorption from 
carboxymethyl chitosan films loaded with phospholipid-bile salts-mixed micelles as mucoadhesive 
buccal films resulted in 2.69-fold increase in bioavailability [166], with no toxic effect on buccal 
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mucosa.  Molavi et al. (2008) prepared polymeric micelles of less than 90 nanometers by 
encapsulating Cucurbitacin B in PEO-b-PCL and PEO-b-PBCL [167]. PEO-b-PCL micelles 
showed superiority in maintaining a sustained release of hydrophobic Cucurbitacin B, thereby 
limiting the rate of STAT3 activation in murine cancer cell line. Patel et al. with the help of 
molecular dynamics simulation studies predicted that the increasing PCL/PEO ratio in PEO-b-
PCL-Cucurbitacin B micelles would reduce the drug release rate [168], due to polar intermolecular 
interactions.  Docking energy analysis showed that the increase in ratio would further favor 
additional hydrogen bond formation between the molecule and poly(ɛ-caprolactone). Cheng et al. 
prepared berberine hydrochloride modified phospholipid complex loaded Cucurbitacin B (CUB-
PLC-BER) as a formulation and tested its delivery and efficacy against cholangiocarcinoma in 
2015 [169]. Berberine hydrochloride is known for stimulating bile release, hence was believed to 
contribute to sustained and prolonged drug release.  Cucurbitacin B loaded with phospholipids and 
berberine hydrochloride had higher drug delivery rate, and was more cytotoxic to the cancer cells 
in both in vitro and in vivo.  Wang et al. encapsulated Cucurbitacin B in glycosylated solid lipid 
nanoparticles [170]. Administration of the formulation resulted into significant increase in targeted 
cytotoxicity, with overall target specific efficiency of nearly 64%, where the conventional 
formulations showed only 23-26%. 
You et al. (2015) predicted direct relation between STAT3 protein localization and 
autophagy [171].  STAT3 in cytoplasm inhibited autophagy via sequestration of EIF2AK2 and 
interaction with FOXO 1/3.  Cytoplasmic localization initiated direct protein-to-protein interaction 
and impeded autophagy by countervailing autophagy related proteins.  Nuclear STAT3 attuned 
autophagy via transcriptional regulation of autophagy-related genes such as the BCL2 family.  It 
is mediated at the genetic level where STAT3 activation may prompt genetic remodeling and 
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attenuation of autophagy.  Mitochondrial translocation of STAT3 constitutively suppressed 
autophagy. Studies reported that Cucurbitacin B and derivatives interfered with the activation of 
STAT3 [37, 40, 48, 84, 95, 102, 106-108, 114, 115, 120-122, 125, 126, 143, 172]. Autophagy 
signaling is a fairly new subject. Cucurbitacin B and its role in autophagy is mostly unexplored, 
hence the field is wide blank to fill in. 
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Fig. 8. Two-dimensional chemical molecular structures of Cucurbitacins and Cucurbitacin B. 
Differences between various subtypes. 
Garg et al. 2018 International Journal of Oncology 52(1): 19-37 
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Fig. 9. Summary of anticancer molecular mechanisms (tissue specific) by Cucurbitacin B. All 
stated proteins are either upregulated or downregulated, contributing to the inhibition of 
cancer development. 
Garg et al. 2018 International Journal of Oncology 52(1): 19-37 
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3.8 Summary 
Cucurbitacins, steroids derived from triterpene hydrocarbon, found in a number of plant 
families, are some of the principle compounds, which attribute medicinal qualities to the plant.  
Cucurbitacin B, the bitter toxin, in previous few decades has splendidly verified its cytotoxic 
potential against cancer and other medical conditions.  Through various mechanisms, it suppressed 
the pathogenesis and inhibited the spread of cancer in vitro and in vivo.  It did so via onset of tumor 
suppressor p53 pathway and inhibition of tumor progression Wnt/β-catenin, phospho-RB, NFκB, 
JAK/STAT, PI3K-AKT, and MAPK/ERK pathways.  Treatment with Cucurbitacin B consistently 
upregulated DNA damage and pro-apoptotic protein markers, while downregulated pro-survival 
markers, growth receptors and cell cycle progressors at either transcriptional level or via 
ubiquitination and proteasomal degradation.  Consequently, it caused growth arrest, apoptosis, 
cellular differentiation, and inhibition of proliferation in cancer cells.  It also showed significant 
efficacy against the developing detrimental effects of cardiac, pulmonary, neurological and hepatic 
injuries, psoriasis, infections and lipogenesis.  It also caused STAT3 dependent autophagy.  Bio-
production, efficacy and metabolism of the compound may be improved by means of slight 
chemical modulation such as the use of hydroponics, bio-transformers, micelles and nanomaterials.  
It is not difficult to categorize Cucurbitacin B as an effective anticancer molecule.  It has the 
potential to prevent cancer, delay its progression, and might be able to completely cure it.  Since it 
is procured from the natural sources, it could significantly economize the expenditure against the 
continuously growing disease.  Surprisingly, not one human study to explore the efficacy of the 
molecule has been conducted so far.  Clinical trials for Cucurbitacin B as the mainline-targeted 
anticancer therapy either as an independent effector or as a supplement is warranted. 
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Withania somnifera and Withanone 
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4.1 Introduction 
Withanone (C28H38O6), 6,7-epoxy-5,17-dihydroxy-1-oxowitha-2,24-dienolide, is a C6, C7 
epoxy steroidal lactone with hydroxyl groups at C5 and C17 [173-175]. It is one of the major 
bioactives of the leaves and roots of plant Withania somnifera L., and was first isolated, identified 
and reported 2004. Authors isolated Withanone from Withania somnifera root extracts by means 
of positive ion electrospray ionization-mass spectrometry, and characterized using the external 
standards. Upon analysis using LC-ES-MS chromatography, they found that the Withanone content 
within the extract had retention time of 311.01 minutes, molecular ion 492.8 m/z bound to sodium 
ion, and diagnostic molecular fragments at 470.7, 280.8, and 252.6 KDa each. While the most of 
the operational exploration has been conducted on its close relative Withaferin A due to its distinct 
differential toxicity, Withanone has gained attention recently. Withanone in the recent years of wet 
and dry laboratory exploration has been known for the selective protection that it offers to the 
normal tissue, as discussed later in the below paragraphs. 
Joshi et al. prepared derivatives of Withanone and Withaferin A by modifications at their 
respective 5, 6, and 7 carbons of ring B to study the effect of epoxide group and further modified 
thiiranes, amino alcohols and alcohols [176]. They checked in vitro toxicity against cancer cell 
lines WRL68, CaCO-2, PC-3 and MCF7, and built derivations in order to establish the relationship 
between toxicity and compound chemistry. They showed that Withanone nucleus is comparatively 
less active than Withaferin A, as the latter binds more strongly to its targets. Withaferin A has 
oxidation on 4, 5, and 6 carbons, and has strong anticancer activity, whereas Withanone has 
oxidation at 5, 6, and 7 carbons, and had almost negligible activity against any cancer cell line. It 
did not react significantly for either thiiration or amination reactions. Comprehensively speaking, 
Withanone nucleus showed weak binding. Whereas Srivastava et al. hypothesized and debated that 
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the differential activity of withanolides such as Withanone might be due to the differential channel 
and reaction mechanisms of the catalytic activity of cytochrome p450 within the Withania 
somnifera plant [177]. Besides various pharmacokinetic factors, medicinal efficacy of any 
compound depends upon its absorption and assimilation within the living body. Devkar et al. tried 
to demonstrate this for withanolides using double stage apparatus [178]. They loaded the test 
samples comprising a mixture of major withanolides in the top stage, and separated it from the 
bottom chamber via an epithelial cell monolayer. After an hour of permeabilization, they measured 
the test sample concentration in the permeabilized mixture by HPLC for withanolide concentration. 
Withonone and Withanolide A are non-polar and have low molecular weight, thus were found to 
be highly permeable. On the other hand, highly reactive Withaferin A was completely impermeable 
to intestinal epithelium. 
 
4.2 Sources and Content Manipulation 
Several studies have been conducted to explore withanolide production and transcriptional 
modulation. In 2017 a fungi-elicited cell suspension culture of Withania somnifera was recruited 
to study the same [179]. The authors found that the principle withanolide production was maximum 
when the plant was co-cultured with cell homogenates of 3% P. indica, 5% V. dahliae, 3% A. 
alternate, and 3% F. solani (10.8, 5.8, 4.9, and 3.3 folds higher respectively, against control. They 
elucidated transcriptional changes and found that the key genes of MVA, MEP and biosynthetic 
pathways i.e., HMGR, SS, SE, CAS, FPPS, DXR and DXS were significantly up regulated. They 
found that along with the biomass and other withanolides, there was about 1.5-fold enhancement 
in the synthesis of Withanone. Pathological agents reduce the bioactivity of Withania somnifera 
plant [180]. Leaf spot disease was induced in Withania somnifera plant, which resulted into a 
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significant reduction in total polyphenolic compounds in the plant and a dip in its antioxidant 
potential. They witnessed a decrease in the production of the contents of major withanolides, 
especially Withanone. This was a result of downregulation of genes HMGR, FPPS, SS, SE, CAS, 
PGT, P450, DXS, DXR and PAL, which are some of the key genes involved in withanolide 
biosynthesis in MEP and MVA pathways. WsSGTL1 is a 3β-hydroxy specific sterol 
glucosyltransferase gene, and has catalytic specificity to glycosylate withanolide and sterols [181]. 
Glycosylation stabilizes and alters physiological activities contributing towards the milieu interior. 
Authors induced ectopic overexpression of the gene in Withania somnifera plant, which resulted 
into enhances leaf growth, increased production and reduced accumulation of withanolide content, 
better tolerance against biotic and abiotic stresses, and enhanced recovery after cold stress. 
Sivanandhan et al. in 2012 used methyl jasmonate and salicylic acid based hydroponic 
medium to grow Withania somnifera plant and enhance its withanolide content [182]. Methyl 
jasmonate is a volatile organic compound and has been implicated to play a significant role in seed 
germination, root growth, flowering, fruit ripening and plant senescence. Salicylic acid is a 
lipophilic monohydroxy benzoic acid and a beta hydroxyl acid. It is a stress-signaling plant 
hormone and plays a significant role in defense, growth and development, ion uptake, 
photosynthesis and transpiration. The authors found that supplementation of culture medium with 
150 µM salicylic acid or 15 µM methyl jasmonate for 4 hours resulted in maximum (at least 28-
fold) enrichment of Withanone in the plant roots. The effects due to salicylic acid was superior 
than due to methyl jasmonate. Over-expression of squalene synthase (4-fold) in the tissue cultures 
of Withania somnifera using A. tumifaciens as the transformation vehicle also would have resulted 
in a significant increase in the withanolide content [183]. Co-cultivation of Withania somnifera 
from 6 day old nodal explants alongside with A. tumefaciens for 3 days, and testing of injury 
	55	
	
	
treatments, sonication, vacuum infiltration and their combinations was conducted [184]. 
Transformed plants with vacuum infiltration, sonication, L-cysteine, sodium thiosulphate and 
dithiothreitol exhibited higher b-glucuronidase expression, fertility and withanolide production. 
Chaurasiya et al. clustered a collection of Withania somnifera plant from different geographical 
locations, through DNA, enzymes, and withanolide profile [185]. They found that geographical 
diversity of the plant has little to do with the Withania somnifera bioactives distribution. Bharti et 
al. in 2011 performed the metabolic profiling of fresh leaf and tissue specimens of Withania 
somnifera by high-resolution magic angle spinning nuclear magnetic resonance spectroscopy 
[186]. They identified 41 metabolites, including withanone as one of the principle bioactives.  
Chaurasiya et al. using linear binary gradient solvent system assisted revered-phase HPLC 
analyzed withanolide content in the leaf and root extracts of Withania somnifera, and found that 
Withanone was one of the major constituents in the tissue [187]. They validated their findings via 
photodiode array, evaporative light scattering detection and on-line UV spectra. Withania 
somnifera has five principle developmental stages i.e., vegetative, flowering, fruit-set, fruit-
maturation, and over-maturation [188]. WsSQS, WsSQE, WsCAS, WsCPR1 and WsCPR2 are some 
of the key genes involved in the withanolide biosynthesis in the plant organs. Authors found that 
within the roots, Withanone content was highest in the vegetative stage in two distinct morpho-
chemo-variants of the plant, and this stage was associated with marginal downregulation in the 
expression of all five associated above-mentioned genes. Supplementation of sucrose and nitrogen 
sources like L-glutamine, adenine sulphate, ammonium nitrate, potassium nitrate and sodium 
nitrate in combination with cytokines kinetin and indole acetic acid resulted in higher frequency of 
flowering and fruiting, with uniform distribution of Withanone [189]. Sabir et al. in 2013 
inoculated Withania somnifera leaves in culture supplemented with growth promoting 
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auxinsindole-3-acetic acid, indole-3-butyric acid, α-naphthalene acetic acid, and 2,4-
dichlorophenoxy acetic acid alone or in combinations, and witnessed the increase in overall 
withanolide content upon organogenesis [190]. They found that while the overall withanolide 
expression was highest in shoot and related directly to the stage of organogenesis and green flesh, 
however, the content of Withanone related in the inverse proportion in all aspects. Withanone was 
mostly found in roots, and its expression reduced with growth promoting auxin supplementation. 
Tong et al. in 2011 isolated chlorinated withanolides, including derivatives of Withanone, from 
Withania somnifera and elucidated their structures by spectroscopic methods and X-ray 
crystallography [191]. 
Authors estimated biomass accumulation and withanolide content production by Withania 
somnifera cell suspension culture on supplementation with various chemical or physical parameters 
like auxins, cytokines, carbon sources, agitation speed, organic additives, and seaweed extracts 
[192]. They encountered an overall increase in withanone production with auxinspicloram, 2,4-
dichlorophenoxy acetic acid, indole-3-butyric acid, indole-3-acetic acid and a-naphthaleneacetic 
acid, cytokines kinetin and 6-benzyladenine, increased agitation speed, organic additives l-
glutamine and casein hydrolysate, and seaweed extracts G. edulis and S. wightii. Biosynthesis of 
withanolides in cell suspension culture using shake-flask and bioreactor against time and 
supplementation with chemical elicitors was investigated [193]. They found the maximum 
production of Withanone was achieved on 28th day, when supplemented with 100 mg/L chitosan, 
10 mg/L aluminum chloride, 15 mg/L cadmium chloride, and 6 mM squalene. Upon 
supplementation of Withania somnifera hairy root suspension culture with seaweed extracts G. 
edulis and S. wightii, authors noted 2-3-fold increase in the production of biomass and withanolides 
[193]. Withanone content enhancement was more significant on the supplementation with G. edulis 
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(about 2-3) fold, than with S. wightii (1.2-1.5 fold). We, in 2016 developed a novel method to 
enhance the bioproduction of withanolides by using hydroponics and light manipulation [194]. We 
found that Withanone production may be enhanced by nutrient rich hydroponic cultivation of the 
Withania somnifera and manipulating light conditions. We also found that its total content is higher 
in leaves compared to the roots. Furthermore, recruitment of cyclodextrin as vector for 
encapsulation could significantly improve in vitro delivery of the compound, and should be 
implicated in anticancer treatment. 
 
4.3 Anticancer Activity 
Withania somnifera leaf extract induced selective killing in the cancer cells, with involved 
ROS induction [43, 47]. Widodo et al. in 2010 found that the Withania somnifera leaf extract, 
having Withanone as one of the major constituents, selectively killed the cancer cells at the dose 
of 40 µg/ml. Negligible toxicity was noted in the normal cells. Upon further elucidation into 
molecular mechanism, authors found that Withanone induced oxidative stress in cancer cells via 
ROS induction, along with selective upregulation of p21WAF21 and γH2AX, and altered membrane 
potential in the cancer cells. In 2008, they obtained purified Withanone (i-Factor) from Withania 
somnifera leaf extract (i-Extract) and subjected it to elucidate its anticancer potential [44]. High 
polarity crystal fraction achieved after hexane/ethyl acetate gradients by silica gel column 
chromatography was named as i-Factor. The authors found that Withanone was highly selective in 
killing osteosarcoma cells. Normal to cancer cell IC50 dose ratio was 26.97:32.64. At this dose, 
Withanone significantly suppressed the subcutaneous tumor growth in balb/c neu mice model. In 
vitro analysis suggested that Withanone interrupted with DNA replication and repair, disturbed 
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cellular assembly and organization, caused G2/M phase arrest, abrogation of mortalin-p53 
interaction and induced p53-mediated apoptotic death signaling in cancer cells. 
Vaishnavi et al. in 2012 explored the differential molecular interactions of Withanone and 
Withaferin A with their potentially target proteins by means of in silico studies and further in vitro 
validation [175]. They found that Withaferin A had strong affinity to mortalin, p53, p21 and Nrf2, 
all of which are implicated in stress related apoptotic signaling. On the other hand, Withanone had 
weak affinity and had minimal toxicity effects. Withanone was therefore safe to use for the normal 
cells. Molecular validation confirmed that Withanone downregulated mortalin and Nrf2 and 
upregulated p53, p21, γH2AX at a relatively higher dose than Withaferin A, yet in a dose dependent 
manner. Corresponding genes were not affected, showing that these effects were post-translational. 
In the normal cells, as a result of stress stimuli, p53 tumor suppressor is induced which leads 
ultimately to apoptosis [195]. p53 is a cytosolic protein, which translocates into the nucleus upon 
activation for its function. Exact mechanism of action of mortalin protein is still unknown, but it 
was previously shown to form a complex with p53, thus delaying or preventing apoptosis. Grover 
et al. in 2012 showed by means of in silico model that Withanone could competitively bind to 
mortalin, at the site which is usually the target for the protein-to-protein interaction between 
mortalin and p53. This interaction is over-expressed in cancer cells, and is minimal in the normal 
cells. Thus, the treatment of normal cells with Withanone was predicted to inhibit apoptosis by 
abrogating mortalin-p53 complex leading to delay in senescence. Same mechanism could be 
applicable to caused nuclear translocation and functional reactivation of p53 in the cancer cells due 
to the low dose treatment with Withanone. 
Aurora A kinase is a serine/threonine kinase protein that has critical role during mitosis and 
cytokinesis [196]. It is found to be upregulated in various cancer types and adds to genetic stability. 
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It functions through its interaction with TPX2, which was also found to be upregulated in cancer 
models. Authors via in silico model found that Withanone could specifically target and disrupt the 
TPX-Aurora A complex. Thus, its treatment resulted into dissociation of the complex and 
disruption of normal mitotic spindle assembly, thereby causing genetic instability and proliferative 
failure. In vitro model validated the results that Withanone treatment led to simultaneous 
downregulation of Aurora A and TPX2 in HER2-/ER+ breast cancer cells. Moreover, survivin is 
one of the hallmark proteins associated with the survival of tumor cells. It is often found to be 
activated in major cancer subtypes such as breast, prostate and colorectal cancer. It inhibits caspase 
cleavage that could lead to apoptosis in cancer cells. Withanone inhibited survivin [197]. 
Withanone according to the in silico studies was shown to be docking with BIR5 domain of 
survivin protein.  
Withanone and Withaferin A are close relatives different by only one epoxy and two 
hydroxyl position, yet contrast tremendously in their cytotoxicity and molecular mechanism of 
action. Withanone promotes survival to the normal cells, whereas Withaferin A is highly toxic to 
the cancer cells. While Withaferin A downregulated Notch proteins through their cleavage and 
antagonist transcriptional activation of associated proteins, these effects were absent when the cells 
were treated with Withanone [198]. Similarly, while Withaferin A caused severe disruption of 
normal spindle morphology during the M-phase leading to inhibition of normal mitotic division 
and growth arrest in the breast cancer cell lines, Withanone had no such effect [199, 200]. 
Withanone also had no effect on experimentally-(TNFα/TGFβ)-induced epithelial to mesenchymal 
transformation of the breast epithelial cell line, while its toxic relative had therapeutic effect [201]. 
Gao et al. in 2014 developed a combination of both in the ratio of 20:1 by weight, respectively 
[202]. They found that the combination showed synergism. Withaferin A pre-possessed with anti-
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migratory, anti-invasive and anti-angiogenic effects, acquired selectivity in cytotoxicity in 
combination with Withanone. It caused significant downregulation in hnRNP-K, VEGF, mortalin, 
p44, and MMP2 protein expression. These results were validated using in silico model and in vivo 
model. 
Shah et al. tested the anticancer effects of alcoholic extract of Withania somnifera leaves in 
glioblastoma cells [203]. Withanone is one of the major constituents in the Withania somnifera leaf 
extracts. They found that the Withanone caused G2/M-S phase cell growth arrest, delayed the 
wound scratch cell migration, and induced astrocytic differentiation in rat and human glioma cell 
lines, with upregulation of GFAP and NCAM. There was evidence to suggest pancytoplasmic 
redistribution of mortalin protein from perinuclear sites, suggesting the role of mortalin in the 
dynamics of glio-differentiation. They also tested if the low dose of Withanone could have stress 
protective and differentiation inducing potential in glioblastoma and neuroblastoma cells [204]. 
Brain cancer cells treated with 2-5 µg/ml Withanone demonstrated significant reduction in cell 
viability with increased LDH release in H2O2 stressed cells. They also exhibited downregulation 
of stress-induced ROS generation and γH2AX expression, and upregulation of GFAP, NF200, 
MAP2 and mortalin levels. Kataria et al. developed an aqueous based extract of Withania somnifera 
leaves, and screen it to check differentiation induction from immortalized rat hypothalamic GnV-
3 cell line into neuroendocrine variety [205]. The extract caused a dose-dependent toxicity in the 
cells. At the sub-toxic doses, the authors found that the cells treated with the extract acquired a 
differentiated morphology close to preoptic GnRH neurons. This was associated with an 
upregulation of PSA-NCAM and MAP2, with GnRH expression upregulation and release.  
 
4.4 Toxicity Revocation 
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In the normal cells, Withanone delayed induction of senescence [206]. While selectively 
toxic to the cancer cells, Withanone protected the normal cells against various toxic stimuli. It 
protected the normal cells against the toxicity caused by its own close cytotoxic relative Withaferin 
A. It increased the mitotic potential of the cells via decrease in accumulation of p21WAF1 expression, 
protection against hydrogen peroxide and ultraviolet radiation mediated oxidative stress, and 
induction of proteasomal activity. Morphologically in the absence of any stress, there was no cell 
toxicity visible in the normal cells. in cancer cells, however, after exposure to the 
UV/H2O2/epoxomyxin, the induced stress resulted into suppression of cell proliferation, effects of 
which were significantly abrogated with Withanone treatment. Treated cells exhibited induction of 
ROS, downregulation of p53 and γH2AX and upregulation of proteasomal activity. Withanone 
possesses immunostimulatory potential [207]. Khan et al. in 2009 found that the in vitro treatment 
of T cells (CD3+, CD4+, CD8+, and CD19+) with Withania somnifera leaf extract caused dose 
dependent proliferation (up to 25 mg/kg Withania somnifera L.) and increased their ability to 
secrete IL2 and INF-γ. In Con A primed splenocytes, it enhanced Th1 cytokine IFN-γ expression, 
hence positively contributing to immunity. Further chemical and molecular characterization 
showed them that these effects were due to 2,3 dihydro-3-sulphonile Withanone derivative present 
within the extract. Withanone derivative was responsible for skewing to Th1 immune polarization 
via stimulation of the expression of IFN-γ and B cell switch over for the secretion of IgG2α, 
coupled with enhanced expression of integrins and co-stimulatory molecules. 
Leishmaniosis is a vector-borne parasitic disease, encircling about 0.7 to 1 million global 
new cases, claiming the most risk with poverty, malnourishment and poor hygiene status. It kills 
about 20000-30000 patients, each year [208]. Most pharmacotherapy strategies to its cure at present 
have failed. Although the structure of protozoan protein kinase C is difficult to predict, it is 
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implicated in some of the vital enzymatic reactions in the parasite that lead to disease according to 
the previous studies. Grover et al. in 2012 predicted and developed the structure of Leishmanial 
protein kinase C, and via in silico tools found that Withanone holds promising docking capacity to 
inhibit its activity [209]. They found that the Withanone showed a significantly high binding 
affinity (-22.57 kCal/mol) with stable molecular docking simulations. It was suggested that 
treatment or supplementation to Leishmanial patients with Withanone could significant contribute 
to control the disease and associated deaths. Wube et al. in 2008 shed light to the implications of 
the variations in the structural differences within withanolides [210]. Certain cyclooxygenase 
(COX) and Leukotriene (LTB) enzymes are known to promote inflammation, cell proliferation and 
angioneogenesis. COX-2/LTB4 inhibitors are hence directly indicated in suppression of 
inflammation. Withanolides’ interaction with these enzymes was studied via in vitro bioassay at 
50 µM molecular concentration. Authors found that few withanolides derived from the bark of 
Discopodium penninervium demonstrated superior COX-2 and LTB4 inhibition than the others. 
However, Withanone was not one of them. 
Scopolamine is a cholinergic antagonist, known to contribute to amnesia [211]. It caused 
cytotoxicity in human neuroblastoma and rat glioma cells, associated with downregulation in the 
expression of BDNF, GFAP, NF-H, MAP2, PSD95 and GAP43 and upregulation in the expression 
of γH2AX and ROS markers in a dose and time dependent manner. Treatment with Withanone 
reversed the scopolamine induced cell toxicity and associated molecular expression of proteins. 
Methoxyacetic acid is an industrial product used as gelling and stabilizing agent and is a major 
metabolite of ester phthalates [212]. It was shown to cause premature senescence in normal cells, 
associated with ROS induction and DNA and mitochondrial damage. Normal cells treated with 
Withanone before and after exposure to methoxyacetic acid exhibited a decrease in ROS generation 
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and associated intracellular damage. This was supported by molecular elucidation of Nrf2 mediated 
cell defense pathway and proteasomal degradation. N-methyl-D-aspartate (NMDA) is water-
soluble glutamate neurotransmitter mimicking amino acid derivative, an excitotoxin, which 
induces accumulation of calcium ions intracellularly leading to ROS generation, loss of 
mitochondrial membrane potential, cytochrome c release, caspase and PARP upregulation and 
cleavage, lipid peroxidation, indicating DNA damage and prompting of death signaling [213]. 
Withanone pretreated in neuron-like (N2α) cells offered protection against NMDA-induced 
excitotoxicity and prevented their dose dependent cell death. It alleviated BAX/BCL2 ratio, 
prevented ROS generation, attenuated calcium ion release and accumulation, normalized 
mitochondrial membrane potential, downregulated cytochrome c release, caspase/PARP 
activation, and malondialdehyde levels.  
 
4.5 Anti-inflammatory potential 
Gupta and Kaur proposed the anti-inflammatory potential in extract from Withania 
somnifera leaves [214]. They prepared a water extract from the leaves, and pretreated it to β-
amyloid and lipopolysaccharide-stimulated primary microglial and BV-2 microglial cells. The 
pretreatment resulted into extensive morphological changes in the cells, proliferation suppression, 
and G0/G1 and G2/M phase growth arrest in activated microglia, with associated downregulation of 
PCNA, cyclin D1, AKTphospho, MHC II, Ibα1, NFκB, AP1 and ROS generation, and attenuation of 
TNF1, IL1B, IL6 and RNS. Withania somnifera leaf extract also delayed migration of activated 
microglia and downregulated associated MMPs. They hypothesized that these effects were 
attributed mainly due to the presence of Withanone. Toll-like receptors are the proteins critically 
involved in the development and regulation of the innate immune system [215]. They recognize 
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and act on the pathogen after they have entered the parenchyma after crossing the guarding mucosal 
epithelium. They can be classified from TLR1 to TLR13, out of which TLR4 is a transmembrane 
protein and its activation stimulates cytokines and complement proteins. Excess stimulation may 
lead to cellular injury and eventually death. This mechanism operates through modulation of 
proinflammatory cytokines and proteins such as MAPK and NFκB. Purushotham et al. by 
computational studies showed that Withanone could suppress TLR4-activated inflammatory 
process, through suppression of LPS-induced cytokines in leukocytic macrocytes. They validated 
their results experimentally and showed that Withanone suppressed inflammatory process in 
TLR4-associated system via downregulation of MAPK and NFkB pathways. This was further 
supported by downregulation of TNFα, IL6, ERKphospho, p38phospho, JNKphospho and IκBα in a dose 
dependent manner. Recently Pandey et al. (2017) demonstrated that Withanone attenuated 
inflammatory cytokines TNFα, IL-1β, IL-6, MCP-1 and nitric oxide, lipid peroxidation and β- and 
γ- secretase enzymatic activity, and reversed the decline in acetyl choline and glutathione activity, 
demonstrating its cognitive skill improvement and multifunctional neuroprotective effect [216]. 
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5.1 Introduction 
Cancer is a highly complex disease arising from a single mutated cell, characterized by its 
immortalization, rapid and uncontrolled proliferation to form a clinical lump, and compromise in 
the function of various organ systems including cytoskeleton rearrangements and hormonal 
dysregulation. World health organization has already labelled cancer as the largest life taker in the 
world, especially in the developed counties, which is likely to rise to more than 26 million annual 
new cases by 2026 and cause global epidemic (WHO 2018). Cancer cells are most consistently 
defined by continued proliferation, insensitivity to stress and DNA damage induced growth arrest 
that are tightly controlled in normal cells. At molecular level inactivation of one or more tumor 
suppressor proteins and activation of a variety of oncogenic signaling have been reported with 
carcinogenesis [217-219]. Malignantly transformed and metastatic cancer cells exhibit enrichment 
of proteins including MMPs, Vimentin, VEGF, mortalin and hnRNP-K [220, 221]. hnRNP-K 
protein has been shown to regulate MMPs and VEGF and cancer cell phenotypes including 
neoplastic stage, genomic instability and cell migration/invasion [220, 222, 223]. Mortalin is a 
hsp70 family stress chaperon implicated in carcinogenesis, metastasis, EMT and stemness of 
cancer cells and has been shown to regulate hnRNP-K [224-228]. Mortalin was shown to inhibit 
transcriptional activation and apoptotic functions of p53 by its retention in cytoplasm [229-231]. 
Remarkably, anti-mortalin molecules were shown to cause growth arrest, and decrease in EMT and 
migration characteristics [195, 225, 229, 231-236]. 
Replicative senescence is an irreversible growth arrest that normal cells enter as they 
exhaust their predetermined proliferative capacity [237]. It acts as a strong tumor suppressor 
mechanism and may serve as an effective anticancer strategy [238]. Lamin A & C are often 
upregulated in cancer cells and responsible for nuclear strength and enhanced DNA repair [239] 
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that is tightly regulated by MRN (MRE11-RAD50-NBS1) complex (enriched in cancer cells) 
[240]. Depletion of lamin A and MRN complex proteins have been shown to cause senescence like 
growth arrest in cancer cells and have been predicted as potential targets for cancer therapy. 
Cucurbitacin B (19-(10à9β)-abeo-10-lanost-5-ene triterpene) is a steroid bioactive with 
peculiar bitter taste and cytotoxic properties commonly found in the plants of Cucurbitaceae and 
other families such as Brassicaceae, Salicaceae, Chrysobalanaceae, Tricholomalaceae and 
Begoniaceae. It has been acknowledged to possess potent anticancer properties [29, 40, 82-87, 
241]. However, it caused acute toxicity to animal tissues in in vivo assays [53]. An FDA report 
from 1955, follow-up in 1983, and several other assessments have reported that the overdose of 
Cucurbitacin B in animals caused abdominal cramps, diarrhea, and occasional vertigo, syncope, 
acute pulmonary edema and respiratory arrest and death [241]. To corroborate this information, we 
previously showed that Cucurbitacin B was not only toxic to the cancer, but also to normal, cells 
[29].  
Withanone (6,7-epoxy-5,17-dihydroxy-1-oxowitha-2,24-dienolide) is a C6, C7 epoxy 
steroidal lactone with hydroxyl groups at C5 and C17, and one of the major bioactives of the plant 
Withania somnifera L. [173, 175]. [44, 47] found that Withanone was selectively toxic to the 
osteosarcoma cells and caused irreversible damage via interruption of DNA replication and repair, 
disturbance in cellular assembly and organization, mortalin-p53 interaction abrogation, and p53-
mediated apoptotic death signaling in cancer cells. Several other studies have advocated anti-
inflammatory and anti-stress potential of Withanone [204, 212, 215, 216]. It has been shown to be 
less active than its toxic relatives due to oxidation at 5, 6, and 7 carbons in its chemical structure 
[176]. This property could translate into weak binding affinity of Withanone to the cellular stress-
related proteins in cancer cells [195]. It was shown to delay the replicative and stress-induced 
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premature senescence in normal cells [206, 212]. It was shown to protect brain derived cells from 
oxidative and glutamate stresses [204, 205, 242, 243] and was found responsible for recovery from 
scopolamine induced memory loss in mice model [211, 244, 245]. When used in combination with 
Withaferin A, it was shown to reduce the toxicity of normal cells; the combination retained the 
anti-migration, anti-angiogenesis and anti-tumor potentials in vivo [202].  
In this study, we formulated combinations of Cucurbitacin B and Withanone (CucWi-N) 
and achieved one with selective toxicity to cancer cells as well as potent antitumor and anti-
migration activities.  Bioinformatics analyses endorsed higher affinity of CucWi-N to mortalin as 
well as hnRNP-K proteins, and was supported by cellular and molecular assays. We report that 
CucWi-N caused induction of replicative senescence in cancer cells selectively by targeting 
proteins involved in proliferation and migration and translated well to effective inhibition of tumor 
growth and metastasis in vivo.  
 
5.2 Materials and Methods 
5.2.1 Cells and reagents 
A549 (non-small cell lung cancer) and TIG-3 (normal skin fibroblast) cells were cultured 
in Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen) supplemented with 5% fetal bovine 
serum and 1% penicillin/streptomycin in a humidified incubator (37°C and 5% CO2). Cucurbitacin 
B (Sigma-Aldrich, Tokyo, Japan) and Withanone (Funakoshi) were dissolved in DMSO to prepare 
100 mM and 50 mM stocks, respectively. Working solutions (10 µM for Cucurbitacin and 5 mM 
for Withanone) were also prepared in DMSO and stored at -20oC in small aliquots. Antibodies 
against Caspase 3 (SC-7148, Santa Cruz), Caspase 9 (SC-7885, Santa Cruz), CDK2 (SC-163, Santa 
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Cruz), CDK4 (SC-260, Santa Cruz), Cyclin D1 (SC-20044, Santa Cruz), Cyclin E (SC-481, Santa 
Cruz), Fibronectin (SC-52331, Santa Cruz), hnRNP-K (4675S, Cell Signaling), Lamin A/C 
(4777S, Cell Signaling), MMP2 (SC-10736, Santa Cruz), MRE11 (NB100-142, Novus 
Biologicals), NBS1 (NB100-143, Novus Biologicals), NFκBp50 (SC-7178, Santa Cruz), p38phospho 
(4511S, Cell Signaling), p44phospho (4370S, Cell Signaling), p53 (SC-6243, Santa Cruz), p70S6K 
(SC-8416, Santa Cruz), PI3K (SC-1637, Santa Cruz), pRBphospho (9307S, Cell Signaling), Rad50 
(Ab89, AbCam), Survivin (SC-10811, Santa Cruz), VEGF (SC-507, Santa Cruz), Vimentin (SC-
6260, Santa Cruz), α-Tubulin (SC-53646, Santa Cruz), β-Actin (ab49900, AbCam) were used for 
immunoblotting and immunostaining. Mortalin and CARF antibodies [228, 246], and recombinant 
mortalin protein [247] were generated in our laboratory. 
 
5.2.2 Cytotoxicity assays 
Cytotoxicity of Cucurbitacin B, Withanone and their combination (CucWi-N) to A549 
and TIG-3 cells was determined by MTT (3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) assay. Cells (2X103/well) were plated in 96-well plate and allowed to settle overnight, 
followed by treatment with varying doses of the compounds. The control (DMSO) or treated cells 
were incubated at 37°C and 5% CO2 for 48 hrs followed by addition of 10 µL of phosphate buffered 
saline (PBS) dissolved 5 mg/mL MTT (M6494, Life Technologies) and continued with incubation 
for 4 hours.  Media containing MTT was aspirated out and replaced with DMSO. The plates were 
placed on a shaker for 5 min followed by measurement of optical density at 570 nm using Tecan 
infinite M200® Pro microplate reader (Tecan Group Ltd., Mannedorf, Switzerland).  Cell viability 
was calculated in percentage against the DMSO-treated control. 
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5.2.3 Crystal Violet staining 
A549 and TIG-3 cells (105 /well) were plated in 6-well plates, and cultured either in 
control or CucWi-N-supplemented medium for 48 hrs.  The cells were then fixed in 100% methanol 
and stained with 0.5% Crystal Violet stain for 2 hours. The plates were washed and dried, and 
visualized under Nikon Eclipse TE300 inverted phase contrast microscope at X400 magnification. 
 
5.2.4 QCV assay 
A549 cells (5X102/well) were plated in a 6-well cell culture dish and cultured either in 
control or CucWi-N-supplemented medium for 8-10 days (until colonies appeared in control 
cultures) with regular change in medium on every alternate day. Colonies were fixed in 
methanol:acetone (1:1) and stained with 0.5% Crystal Violet for overnight followed by washing 
with ultrapure water to remove the excess stain. The plates were air-dried and photographed under 
Nikon Eclipse TE300 inverted phase contrast microscope at X400 magnification. Colonies from 
three wells and three experiments were counted and analyzed for size in three independent 
experiments i.e., clonogenicity, long-term cell viability and cellular morphology. 
 
5.2.5 Immunoblotting 
A549 and TIG-3 cells (5X105/well) were plated in 6-well plates and allowed to settle 
overnight, followed by culture either in control or CucWi-N-supplemented medium. At the end of 
48 hrs, cells were harvested and washed with PBS twice, followed by lysis in RIPA buffer (89900, 
ThermoFisher) containing complete protease inhibitor cocktail (4693159001, Roche Applied 
Science) on ice for 45 mins. Cell (or tumor) lysates (containing 10-40 µg protein) were separated 
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on a SDS-polyacrylamide gel using Mini-Protean® Tetra cell equipment (Bio-Rad, Hercules, CA), 
and transferred onto PVDF membrane (Millipore, Bedford, MA) by Mini Trans-Blot® 
Electrophoretic Transfer Cell (Bio-Rad). Membranes were washed with TBST (0.1% Tween 20 in 
TBS) for 5 mins, blocked with 3% bovine serum albumin protein dissolved in TBST for 45 mins, 
incubated with primary antibodies diluted in 0.05% TBST for overnight at 4°C, washed with TBST 
thrice for 10 mins each, incubated with horseradish peroxidase-conjugated secondary antibody 
(goat anti-mouse HRP (31430, ThermoFisher) or goat-anti-rabbit HRP (31460, ThermoFisher) 
diluted in 0.05% TBST for 3 hrs at room temperature, washed with TBST thrice for 10 mins each, 
and finally developed using chemiluminescence solution (GE Healthcare, UK) and visualized using 
Lumino Image Analyzer equipped with CCD camera (LAS3000-mini; Fuji Film, Tokyo, Japan). 
 
5.2.6 Immunocytostaining 
A549 and TIG-3 cells (2.5x104/well) were plated on coverslips in 12-well plates and 
allowed to settle overnight, followed by culture either in control or CucWi-N-supplemented 
medium. At the end of 48 hrs, cells were fixed in methanol:acetone (1:1) on ice for 5 minutes, 
rinsed with PBS thrice, permeabilized with 0.2% PBST (0.2% Triton-X in PBS) for 20 mins, 
washed with PBS for 15 mins, and blocked with 2% bovine serum albumin protein dissolved in 
PBST for 45 minutes. Fixed cells were incubated with primary antibodies diluted in blocking 
solution against various proteins overnight at room temperature, washed with PBS-PBST-PBS for 
15 mins each, incubated with either Alexa-Fluor 488 goat anti-mouse IgG (A11029, Life 
Technologies) or Alexa-Fluor 594 goat anti-rabbit IgG (A11037, Life Technologies), depending 
upon the source of the primary antibodies, diluted in blocking solution for 3 hrs in dark, washed 
with PBS-PBST-PBS for 15 min each, incubated with Hoechst 33342 antibody (H3570, Invitrogen 
	72	
	
	
Molecular Probes) for 10 min in dark, washed with PBST-PBS for 15 min each, rinsed with 
ultrapure water twice and mounted on glass slides using FA mounting solution (FAMF, VMRD). 
The cells were then visualized for immunofluorescence under Zeiss Axioplan 2 upright 
fluorescence microscope at X400 magnification. 
 
5.2.7 Flow cytometry 
A549 cells (2X105/well) in 6-well plates were synchronized for cell cycle phase by serum 
starvation for which, they were cultured successively in 5%, 1%, 0% FBS-supplemented DMEM 
for 24 hrs each, and then recovered in 5% FBS-supplemented DMEM for 24 hrs, followed by 
culture in either control or CucWi-N-supplemented medium for 48 hours.  Cells were harvested by 
trypsinization. Two hundred thousand cells per milliliter counted using an automated cell counter 
(TC20TM, Bio-Rad) were washed twice and re-suspended in 300 µl PBS. Cells were fixed by adding 
700 µl ice cold 100% ethanol slowly with mild vortexing. Fixed cell pellets were incubated in -
20°C for overnight, centrifuged at 2000 rpm, washed twice with PBS and centrifuged. RNA was 
degraded by incubation with 100 µg/ml RNAse (EN0531, ThermoFisher) at 37°C for 90 mins. 
Suspensions were centrifuged at 2000 rpm for 7 mins, and re-suspended in 200 µl Guava Cell 
Cycle Reagent (4500-0220, Millipore) and incubated at room temperature for 30 mins in dark, 
diluted in 1-2 mL PBS and taken up for data acquisition and cell cycle analysis on Guava PCA-96 
system. 
 
5.2.8 Senescence induction 
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Control or CucWi-N treated cells were serially passaged by 1:16 split ratio until they attained 
senescence and stopped dividing. Culture medium supplemented with or without CucWi-N was 
replaced every 2-3 days.  Cells were harvested for protein, mRNA, immunofluorescence analyses 
at each passage. To induce replicative senescence in A549 cells, cells were subjected to 5 µM 
doxorubicin (D1515, Sigma-Aldrich) for 1-2 hrs followed by culture in either the control or 
CucWi-N-supplemented medium under standard incubation conditions.  
 
5.2.9 Mortalin ELISA 
Cell lysates (containing 100 µg protein) derived from control or CucWi-N treatment with 
or without doxorubicin induced senescence were plated into clear flat bottom polystyrene Costar® 
96-well plate (3632, Corning) pre-coated with 100 ng/mL antibody to mortalin diluted in coating 
buffer (421701, BioLegend) and diluent buffer (421203, Biolegend), and incubated for overnight 
at room temperature. Wells were then washed with washing buffer (0.05% Tween 20 in PBS) thrice 
for 1 minute each, and reloaded with 100 ng/mL antibody to mortalin diluted in diluent buffer. The 
plate was incubated for overnight at room temperature, following which it was washed thrice for 1 
minute each and incubated with 100 ng/mL horseradish peroxidase-conjugated secondary antibody 
goat anti-mouse HRP (31430, ThermoScientific) diluted in diluent buffer for 3 hours at room 
temperature. The plate was washed thrice for 1 minute each and then incubated with TMB substrate 
(421101, BioLegend) for 30 minutes for color development. Stop solution (423001, BioLegend) 
was added onto the substrate and mixed, and optical density was measured at 450 nm using Tecan 
infinite M200® Pro microplate reader (Tecan Group Ltd., Mannedorf, Switzerland). Recombinant 
mortalin protein diluted in diluent buffer was used as the standard. Mortalin protein concentration 
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was calculated against the control using the slope equation obtained in the standard curve and the 
graph was plotted in percentage taking the control as 100%. 
 
5.2.10 Would scratch migration assay 
A549 cells (1.5x105 well) were plated in a 6-well plate and allowed to settle overnight.  A 
linear scratch was made using a sterile pipette tip (200 µl) to simulate an area devoid of cells. The 
cells were either cultured in control or CucWi-N-supplemented medium. Movement of cells into 
the scratched area was monitored under Nikon Eclipse TE300 inverted phase contrast microscope 
at X400 magnification every 6 hrs. Photographs of scratch and migrating cells were captured every 
24 hrs. 
 
5.2.11 Invasion assay 
Invasion assay was carried out using BioCoat™ Matrigel™ Invasion kit (3-354480, 
Corning®). A549 cells (5X104/well) were suspended in 0.5 ml serum free DMEM were plated into 
the top of invasion inserts and the bottom well of a 24-well plate was filled with 0.75 ml DMEM 
supplemented 10% FBS. After 48 hours, the inserts were transferred to fresh plates and washed 
thrice with PBS. Cells suspended in the MatrigelTM basement membrane matrix at the bottom of 
each insert were fixed in methanol:acetone (1:1) and stained with 0.5% Crystal Violet for overnight 
followed by washing with ultrapure water to remove the excess stain. The inserts were air-dried 
and photographed, followed by visualization under Nikon Eclipse TE300 inverted phase contrast 
microscope at X400 magnification. 
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5.2.12 Bioinformatics 
Molecular docking studies of Cucurbitacin B (PubChem CID 5281316) on mortalin (PBD 
ID 4KBO) protein and Cucurbitacin B, Withanone (PubChem CID 21679027) and their 
combination on hnRNP-K (PBD ID 1ZZI) protein were carried out using AutoDock 4.2 suite. 
Molecular dynamic simulation of the docked complex was studied for 50 ns. 
 Preparation of protein and ligand structures for docking studies: All the protein structures 
used for docking studies were retrieved from Protein Data Bank. For human mortalin apo form of 
ATPase domain with resolution of 2.8 Å was downloaded (PDB ID: 4KBO) [248]. The coordinates 
of p53 protein were extracted from a p53-DNA complex (PDB ID: 4MZR) [249]. The resolution 
of the structure was 2.9 Å. The crystal structure of KH3 domain of hnRNP-K with 15-mer ssDNA 
is available at 1.8 Å resolution (PDB ID: 1ZZI) [250]. The PDB corresponding to only hnRNP-K 
was used for performing the docking experiments. All the three protein structures were prepared 
using the protein preparation wizard of Schrodinger to be used for docking. The missing hydrogen 
atoms were added and the resulting structures were optimized. The other processing steps involved 
removal of bad contacts, bond length optimization, creation of disulfide bonds, capping of protein 
terminals, and conversion of selenomethionines to methionine residues. The short stretches of 
missing amino acids and missing side chains were added using the prime module of Schrodinger.  
The 3-D conformers of natural compounds- Withanone and Cucurbitacin B were obtained 
from PubChem (CID: 21679027 and 5281316 respectively). These molecules were also prepared 
for docking using the LigPrep module of Schrodinger. This ligand preparation protocol generates 
different tautomeric, stereochemical and ionization variants of the small molecules followed by 
energy minimization and flexible filtering.  
	76	
	
	
Docking of protein molecules with natural compounds: The p53 binding site in mortalin 
(253-282 amino acids), mortalin binding site of p53 (323-337 amino acids), and hnRNP-K residues 
comprising the KH3 domain were targeted for docking with the small molecules. A grid was 
generated to cover all the important residues for each of the above-mentioned protein using the 
Glide module of Schrodinger. The prepared natural compounds- Withanone and Cucurbitacin B 
were then docked against the three proteins using Glide’s extra precision (XP) docking protocol.  
The molecular interactions between the protein-ligand complexes were studied using the 
Ligplus program. H-bonds were taken into consideration when the distance between acceptor-
donor atoms was less than 3.3 Å, with maximum hydrogen-acceptor atom distance of 2.7 Å and 
acceptor-H-donor angle greater than 90°. 
Assessing the stability of the docked complexes: To investigate the dynamic stability of the 
docked complexes, molecular dynamics (MD) simulations were carried out using the Desmond 
module of Schrodinger. Firstly, the docked complexes were solvated in a triclinic periodic box of 
TIP3 water and an appropriate number of counter-ions were added to neutralize the system. The 
distance between the walls of the box and the complex was kept 10 Å to prevent the interaction of 
ligand bound protein with its own periodic image. The prepared system was then subjected to 
energy minimization up to a maximum of 3000 steps using a steepest decent method or until a 
gradient threshold (25 kCal/mol/Å) was not reached. After equilibration, the protein-ligand 
complexes were simulated for 50 ns in each case. Optimized Potential for Liquid Simulations 3 
(OPLS3) force field was used to carry out all the simulation experiments. Temperature of 300 K 
and a constant pressure of 1 atm was used with a time step of 2 fs for the production MD. Smooth 
particle Mesh Edwald method was used to calculate long distance electrostatic interactions. For 
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calculating coloumbic short-range interactions a cutoff radius of 9 Å was used. Frames were 
captured after every 4.8 ps of the time interval to obtain the simulation trajectory.  
 A steady RMSD profile of the protein backbone and ligand in reference to the first frame 
over the entire simulation trajectory was used as a measure to assess the stability of the docked 
complexes.  
 
5.2.13 Animal studies 
Athymic balb/c nude female mice (4 wk old) were purchased from NihonClea, and 
acclimatized for two weeks under standardized animal house conditions. Animals were orally pre-
fed with either vehicle (0.1% carboxymethyl cellulose) or with CucWi-N-supplemented vehicle 
(Cuc 1 mg/kg + Wi-N 10 mg/kg BW) in 200 µl suspension every alternate day for a week. Animals 
were injected with healthy A549 cells (5X106/injection) in 150 µl PBS subcutaneously (for 
subcutaneous xenograft) over the left and right flank (ventrally), and intravenously (for lung 
metastases) through tail vein injections. Upon emergence of tumor buds from xenografts, mice 
were regularly fed with the oral suspensions thrice a week for nearly 8 weeks. Tumors were 
regularly monitored and sized with Vernier caliper.  Tumors volume was calculated using the 
formula V=(LxW2)/2 with caliper measurements of length (L) and width (W) of the tumors. Mice 
were sacrificed by cervical dislocation before tumors grew to about 1.5 cm length and were 
examined for internal tumors and lung metastasis. Dissected tumors were isolated and lysed in lysis 
buffer for protein analysis. A qualitative hemolytic assay to test safety of CucWi-N from causing 
erythrocyte lysis was performed. Blood extracted from a healthy mice heart was diluted with 
diluent buffer (0.85% NaCl containing 10 mM CaCl2) to obtain 2% RBC suspension. 150 µl 
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suspension was mixed with 75 µl diluent buffer and 75 µl of CucWi-N (Cuc 1 µM + Wi-N 50 µM, 
in 100% DMSO) by gentle pipetting. The mixture was incubated at room temperature for 1 hr, 
followed by centrifugation at room temperature for 5 min at 16000 rpm. 200 µl of the supernatant 
was loaded into a 96-well plate well to read absorbance at 540 nm. Ratio of absorbance 
corresponded to the degree of hemolysis. 0.2% Triton X-100 in diluent buffer was taken as the 
positive control. The antioxidant enzyme activities of catalase (CAT) and malondialdehyde (MDA) 
levels in the plasma were measured as per manufacturer’s instructions using Catalase assay kit 
(707002, Cayman Chemical) and TBARS colorimetric microplate assay kit (FR40, Oxford 
Biomedical Research), respectively. All animal experiments were performed following the 
protocols for animal experiments recognized and approved by Institute Animal ethical committee. 
 
5.2.14 Statistical analysis 
All the calculations were done using Microsoft® office. Statistical significance was 
calculated by unpaired t test of GraphPad software® (2017) using mean, SD and N from three 
independent experiments, and shown as *p<0.05, **p<0.01, ***p<0.001. 
 
5.3 Results 
We investigated dose-dependent toxicity of Cucurbitacin-B (Cuc) to human cancer (A549) 
and normal (TIG-3) cells.  As shown in Fig. 10, Cuc showed higher cytotoxicity to the normal 
cells. Withanone (Wi-N), on the other hand, was not toxic to either of the cell types at doses from 
2.5 to 10 m M in short term (48 h) cytotoxicity assays. We next tried various combinations of two 
compounds and found that a Cuc:Wi-N combination in a ratio of 1:500 was more cytotoxic to 
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cancer than the normal cells (Fig. 11). Low, medium and high doses of CucWi-N resulted into 
~15%, ~30% and ~50% loss in A549 cell viability. These doses were nearly non-toxic (>90% cell 
viability) to the normal cells. We selected these three doses (Fig. 12) to analyze the mechanism(s) 
of their anticancer activity by biochemical, molecular and imaging assays. In Quantitative Cell 
Viability (QCV) assay, direct observation of control and treated (low and medium; 48 h) cells under 
the microscope revealed stressed morphology (spindle shaped flat and large cells) in a dose 
dependent manner in cancer, but not normal cells (Fig. 13). CucWi-N treated cancer cells showed 
inhibition of clonogenicity in a dose dependent manner (Fig. 14). Of note, the low dose that resulted 
in only 20% decrease in viability in short term (48 h) assays caused significant reduction (80%) in 
colony forming efficiency (10 days). Consistent with this and the above data, the growth analysis 
revealed that inhibition of cell proliferation over 3 days of continual treatment of low dose of 
CucWi-N was more pronounced in the cancer cells than the normal cells (Fig. 15).  
We next performed molecular analysis of growth and apoptosis signaling in cancer and 
normal cells subjected to the treatment of high dose of CucWi-N. We found that whereas CucWi-
N treated cancer cells showed downregulation of CDK-2, CDK-4, Cyclin D1 and Cyclin E, normal 
cells showed increase in most of these proteins (Figs. 16 and 17), indicating selective growth arrest 
in cancer cells by CucWi-N was mediated by downregulation of proteins involved in cell cycle 
progression. On the other hand, analysis of proteins involved in apoptosis showed no significant 
difference in control and treated cells. We next performed flow cytometry and cell cycle analysis 
and found that the CucWi-N indeed caused arrest in the S-phase of cell cycle in the cancer cells 
(Fig. 18). Cells were next treated with high dose for 4 or 24 h.  Microscopic observations of treated 
cancer cells showed changes in nuclear membrane and flattened irregular morphology as early as 
4 h of treatment (Fig. 19). We anticipated that such changes may be mediated by changes in Lamin 
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A/C. Immunostaining of cells with Lamin A/C specific antibodies showed downregulation of 
Lamin A/C in cancer, but not in normal cells, and was remarkably apparent in cells treated for 12-
24 h (Fig. 19). 
Based on the above data on cell cycle arrest and decrease in Lamin A/C, we predicted that 
CucWi-N may induce replicative senescence in cancer cells. In order to investigate this, cancer 
cells were treated with low dose of CucWi-N in a continuous culture regime. As shown in Fig. 20, 
compared to the control cells, treated cells showed slow growth that was clearly apparent in about 
18 days followed by gradual decline in proliferation until the cells stopped dividing in about 60 
days (Fig. 20). Molecular analyses revealed that gradual arrest in growth was associated with 
progressive downregulation of proteins (phosphorylated pRB, hnRNP-K and mortalin) critically 
involved in cell cycle progression and continued proliferation of cancer cells. On the other hand, 
proteins involved in DNA damage signaling and growth arrest (CARF and p53) were upregulated 
(Fig. 21). The results were confirmed by several independent experiments and multiple assays 
including immunocytostaining (data not shown) and ELISA (Fig. 22) that confirmed 
downregulation of mortalin. Induction of DNA damage signaling and growth arrest was also 
endorsed by increase in MRN complex (Fig. 23). We next determined if CucWi-N induced 
selective growth arrest in cancer cells was mediated by this axis by using doxorubicin induced 
senescence model.  Of note, CucWi-N treated cancer cells showed decrease in MRE11, Rad50 and 
NBS1; their senescent derivatives showed milder decrease in MRE11 and RAD50; NBS1 did not 
show any change (Fig. 23) suggesting that CucWi-N-induced selective growth arrest in the cancer 
cells may be mediated by downregulation of one or more members of MRN complex.   
Cancer cells often show increase in their migration capacity resulting into their metastasis 
from the primary to secondary sites in the body. We next examined the migration capacity of 
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control and treated cells by wound scratch and cell invasion assays. We found dose-dependent 
inhibition of migration and invasiveness of the cancer cells treated with CucWi-N (Fig. 24 and 25). 
Since mortalin and hnRNP-K proteins have been shown to be the key regulators of cell migration 
and cancer metastasis [220, 222, 225], we investigated if CucWi-N induced decrease in these 
proteins contributing to the observed phenotypes. Expression analyses of these and other (VEGF, 
Vimentin, MMP2 and Fibronectin) proteins involved in cell migration and invasion indeed showed 
their downregulation in CucWi-N treated cells. Of note, cells treated with not only the high but 
also the low dose showed significant downregulation of expression of these proteins (Figs. 26 and 
27). Furthermore, staining pattern of mortalin was seen to shift from perinuclear (typical of cancer 
cells) to pancytoplasmic (typical of normal cells) and signified induction of senescence as reported 
earlier [29, 251].  
In view of earlier reports that Wi-N activates growth arrest signaling in cancer cells by 
abrogation of mortalin-p53 complexes and reactivation of p53 protein [195], we currently 
examined if Cuc could function in a similar way. Molecular dynamics analysis showed that it could 
bind to mortalin (binding energy of -4.212 kCal/mol) at the Thr267 and Gly269 that are involved 
in interaction of mortalin to p53 (Figs. 28 and 29). Interestingly, MKT-077, that has been shown 
to bind to mortalin was used as a positive control, showed lower binding energy (-2.042 kCal/mol) 
suggesting that Cuc may be a better mortalin inhibitor (Fig. 30). We next examined binding of Cuc 
to p53. Although it showed interactions to p53 residues Thr118 and Lys321, no interactions with 
mortalin-binding domain of p53 (amino acid residues 323-337) [233] were observed (Fig. 31). 
These data suggested that enhanced activity of CucWi-N may involve other mechanisms. We next 
subjected Cuc and Wi-N to molecular docking analysis using hnRNP-K as a target molecule (Fig. 
31 and 32). Individual binding of Cuc and Wi-N showed comparable energy (-2.93 kCal/mol and 
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-2.34 kCal/mol, respectively) (Fig. 30). We then subjected two molecules together (Cuc and Wi-
N) to molecular docking analysis. Interestingly, we found that binding efficacy of Cuc to hnRNP-
K:Wi-N complex was double (-4.69 kCal/mol) as compared to the binding of Wi-N to hnRNP-
K:Cuc complex (binding energy -2.62 kCal/mol) (Fig. 30). During the 50 ns long simulation of the 
triple docked complex (Cuc:Wi-N:hnRNPK) one hydrogen bond involving Cuc and Lys87 residue 
of hnRNP-K was stable during the entire process indicating the high stability of the complex (Fig. 
33). The molecular docking analysis data suggested that CucWi-N may cause stronger inactivation 
of cancer cell proliferation and migration signaling by targeting mortalin and hnRNP-K proteins. 
We next examined subcellular localization and expression level of these proteins in cells treated 
with either the individual compounds or their combination.  As shown in Fig. 34 and 35, cells 
treated with CucWi-N showed stronger downregulation of mortalin and hnRNP-K than Cuc or Wi-
N individually. 
We next tested the anticancer therapeutic potential of CucWi-N in nude mice subcutaneous 
xenograft tumor progression model. Animals orally fed with CucWi-N suspension for 9 weeks 
demonstrated suppression of subcutaneous tumors (Figs. 36 and 37). They also exhibited reduced 
intra-pulmonary metastatic lesions (Fig. 38) and total blood MDA levels (Fig. 39), and increased 
catalase activity (Fig. 39), collectively advocating the anti-carcinogenic, anti-metastatic, and anti-
oxidant effects of CucWi-N. CucWi-N was safe to use in the animal model, since it neither cause 
any significant weight loss or toxicity to the animals, nor it caused hemolysis in vivo (Figs. 37 and 
39). Furthermore, subcutaneous tumors derived from the treated and vehicle animals were 
subjected to protein analysis. As shown in Fig. 40, and in line with the in vitro data, we observed 
consistent downregulation of the key proteins responsible for cancer cell migration, invasion, 
survival and stress signalings (Fig. 40) endorsing the cancer therapeutic potential of CucWi-N.   
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5.4 Discussion 
The process of carcinogenesis involves discrete molecular changes over time resulting in 
not only the aberrant growth of cells and tissues, but also their invasion to the neighboring and 
distant sites. Although the last 2 decades has seen remarkable progress in cancer diagnosis and 
treatment, cancer mortality is increasing exponentially and is expected to double by the next 
decade. All cancers constitute rapidly dividing cancer cells that lose their differentiated 
characteristics and are vulnerable to structural changes and damage. Such characteristics are often 
used as assay system for anti-cancer drug discovery and validation. Conventional treatment for 
benign tumors is surgical resection or radiotherapy; malignant and metastasis tumors are treated 
with chemotherapy. Conventional synthetic chemotherapeutic agents are expensive, cause multiple 
adverse effects and drug resistance, therefore continual development of less toxic and economical 
anti-cancer drugs is warranted. Fridlender et al. have summarized and appraised the anticancer 
potential in a number of herbs [252]. They revealed a profound link in cancer prevention and 
curative therapies using herbs such as allspice, basil, clove, and garlic, etc. Active anticancer 
ingredients from a large number of herbs have been identified in the recent years [253]; autonomous 
or collaborative therapy of these bioactive ingredients or herbal extracts are shown to reduce the 
development and/or progression of a variety of human cancers through various mechanisms [106, 
121, 254-256]. We recently showed anticancer potential in the root extract of the plant Helicteres 
angustifolia and its bioactive Cucurbitacin B (Cuc) [29], which has been acknowledged for its 
anticancer properties in several other studies [40, 82-87, 241]. Unfortunately, it caused acute 
toxicity in vivo [53, 57, 241] and was also toxic to normal cells in vitro [29]. In order to recruit the 
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cytotoxic potential of Cuc for cancer cells selectively, we engineered its cocktail with Withanone 
(Wi-N), a steroidal lactone bioactive of Withania somnifera L., which has been shown to bring 
about negligible toxicity to normal cells [44 {Priyandoko, 2011 #6320, 47, 176, 255]. It was also 
shown to offer side benefits (protection against oxidative and chemical stresses, and lifespan 
extension) autonomously to the normal cells [206, 212, 255]. In combination with Withaferin A, it 
demonstrated selective toxicity to cancer cells and therapeutic potential for suppression of tumor 
growth and metastasis in vivo [202]. In line with this, we developed CucWi-N (a 1:500 molar ratio 
of Cucurbitacin B and Withanone,) and found that it possessed remarkable anticancer activity. It 
was relatively safe for normal cells. Dose response data showed that CucWi-N at even low doses 
inhibited the cancer cell clonogenicity and proliferation. The effect was significantly stronger in 
cancer than in the normal cells (Figs. 10 to 15) and was supported by molecular data including 
selective downregulation of CDK-2/4 and Cyclin D1/E in cancer cells causing cell cycle arrest in 
the S-phase (Figs. 16 to 19). Microscopic observation on the control and CucWi-N treated cells 
showed stressed and flattened morphology in the latter; changes in nuclear membrane were 
observed as early as 4 h consistent with earlier report [96]. Furthermore, we found that CucWi-N 
treated normal cells showed recovery from stressed phenotype. It may be attributed to Wi-N as 
suggested in earlier studies [204, 206, 212]. 
In view of the changes observed in nuclear membrane, we predicted and validated that 
CucWi-N treatment caused laminopathy (lamin-dependent nucleus-mediated destruction of the cell 
morphology) [239, 257] selectively in cancer cells (Figs. 16 to 19). Furthermore, by serial 
passaging of cancer cells in sub-toxic low doses of CucWi-N, we demonstrated that it caused 
replicative senescence (Fig. 20 to 23) - an expected outcome of laminopathy [258, 259]. CucWi-
N-induced senescence in the cancer cells was supported by molecular changes including, gradual 
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downregulation of pRBphospho, hnRNP-K and mortalin, and activation of CARF and p53. pRB 
(Retinoblastoma protein, a major tumor suppressor coded by RB1 tumor suppressor gene) 
phosphorylation and its release from pRB-E2F complex is essential for cell cycle progression [241, 
260]. hnRNP-K, a multifunctional protein enriched in dividing and migrating cells has been 
implicated in proliferation and migration capacities of cancer cells [220, 223]. Mortalin, a stress 
chaperone, has been linked to proliferative and anti-apoptotic characteristics of cancer cells. 
Together, decrease in pRBphospho, hnRNP-K and mortalin expression demonstrated decrease in 
proliferation and cell cycle arrest in CucWi-N treated cancer cells. Furthermore, shift of the staining 
pattern of mortalin from perinuclear (characteristic of cancer cells) to pancytoplasmic 
(characteristic of normal cells) endorsed induction of senescence [225, 230, 232]. This was further 
supported by increase in p53 (tumor suppressor) and CARF proteins, which have been established 
as stress, senescence and growth arrest regulating intracellular protein markers [261-264] and 
shown to be upregulated at the onset of replicative senescence [261, 263]. Consistent induction of 
wild type p53 activity [265] and upregulation of CARF have been shown to cause 
senescence/growth arrest of cells [266, 267]. Furthermore, CucWi-N treated cancer, but not the 
normal, cells showed downregulation of MRN complex. 
Several studies have reported the crucial role of MRN complex (constituted of MRE11, 
Rad50 and NBS1 proteins) in genomic stability, DNA repair mechanisms and induction of 
senescence [240, 268]. It was shown to be tightly associated with DNA-damage mediated repair 
mechanism and delay of senescence by both telomerase and ALT mechanisms. MRN has been 
established as sensor of DNA damage and triggers the repair by regulation and expression of 
several proteins that in turn have been shown to regulate telomere structure, function and 
replicative senescence [269]. Its inhibition results into unresponsiveness to DNA damage gradually 
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leading to senescence [270, 271]. MRE11 has been shown to be central to the DNA repair 
mechanism in telomerase-positive cells [272, 273]. Activated by ATM phosphorylation, it 
promotes local separation of the double stranded DNA helix at the damage site and recruit the 
repair machinery [274]. MRE11 depletion was associated with telomere damage and defective 
nuclease functions [275]. NBS1, on the other hand, was shown to play a crucial role in alternate 
lengthening of telomere (ALT) mechanism of telomere maintenance and cancer cell immortality 
[276, 277]. NBS1 knockdown has been shown to result in impaired DNA damage response, 
accumulation of double stranded DNA breaks and accelerated senescence [278-280]. Of note, 
while MRE11 has been shown to play a key role in telomerase-based immortality, NBS1 was 
shown to be central in ALT-mechanism. We found that CucWi-N treatment caused marked 
inhibition of MRE11 and NBS1 in the cancer cells (Fig. 23) suggesting that it may be effective for 
both telomerase plus and ALT cells. Furthermore, these changes in doxorubicin-induced senescent 
cells were not as pronounced as in cancer cells attributing to the selective induction of senescence 
in the latter. 
Lamin A and C are the most studied lamin proteins, which form a network structuring into 
the nuclear lamina and play a fundamental role in the organization of the nuclear architecture [281-
283]. Lamin expression is directly linked to the structural integrity of a cell and is enriched in 
differentiated cells. It has been shown to mediate nucleo-cytoplasmic trafficking of molecules 
including hnRNP-K and mortalin [226, 284]. Deficient lamina has been shown to give rise to 
laminopathies like conductive cardiac dystrophy, skeletal defects and lipodystrophy [285]. Lamins 
were shown to interact with SUN1, a mammalian inner nuclear envelop mRNA exporter and 
structurally bridge nuclear membrane to cytoskeleton [282]. Knockdown of SUN1 protein resulted 
into indirect laminopathy, cellular morphological defects and an overall downregulation of hnRNP-
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K. On the other hand, MKT-077 (mortalin inhibitor) was shown to cause extensive caspase-
dependent apoptotic cell death, which was mediated by cleavage of PARP and lamin A [283]. 
Foster et al. showed that depletion of lamin A caused cross-linking and folding of mortalin that 
favored the formation of dynamic actin filaments over stress fibers [281]. In light of this 
information, it is suggestive that CucWi-N-mediated decrease in mortalin, hnRNP-K and lamin 
A/C may be linked events. 
Molecular docking analysis of Cuc and Wi-N to 3 target proteins (mortalin, p53 and 
hnRNP-K) revealed that whereas Cuc has strong affinity for the mortalin protein and formed stable 
hydrogen bonds within its p53 binding site, no stable bonding within the mortalin binding site of 
p53 protein was seen (Figs. 28 and 29). Wi-N, on the other hand, has been shown to abrogate 
mortalin-p53 complexes by binding to both the proteins [175]. Docking of Cuc and Wi-N revealed 
comparative affinity hnRNP-K protein (Figs. 31 to 33). Of note when Cuc showed high binding 
affinity when the Wi-N was pre-docked to hnRNP-K (Fig. 30). These data may explain the higher 
therapeutic potential of the CucWi-N combination. In vivo nude mice tumor progression data and 
the protein analysis of tumors from control and CucWi-N fed mice revealed that CucWi-N has no 
toxicity to mice and possesses strong tumor suppression and anti-metastasis capability (Figs. 36 to 
40). Cancer cell metastasis involves upregulation of EMT proteins such as MMPs and Vimentin 
[286, 287], hnRNP-K [220, 222] and mortalin [225]. Of note, CucWi-N inhibited migration and 
invasion capacity of the cancer cells, even at the non-toxic dose, and was supported with the 
downregulation hnRNP-K, mortalin, VEGF, Vimentin, MMP2 and Fibronectin (Figs. 24 to 27). 
Here, we hypothesized and aimed to develop a combination of the bioactives hailing from 
the Indian and Chinese Ginsengs, which could serve as a natural, affordable, and safe anticancer 
drug. Cellular phenotype and molecular analyses provided evidence that it was safe for normal 
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cells and caused replicative senescence in cancer cells. We have demonstrated that CucWi-N 
targets mortalin and hnRNP-K proteins, cause decrease in Lamin and MRN complex proteins 
resulting into the induction of senescence and decrease in the migration of the cancer cells. We 
propose CucWi-N as a potent cancer preventive and therapeutic anticancer cocktail, which 
warrants clinical evaluation.  
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Fig. 10. Effect of CucWi-N on cell survival and multiplication: Dose titration of Cucurbitacin B 
and Withanone on A549 and TIG-3 cells as independent agents over 48 hrs. 
Garg et al. 2018 J Gerontol A Biol Sci Med Sci (Communicated) 
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Fig. 11. Effect of CucWi-N on cell survival and multiplication: Dose titration of Cucurbitacin B 
and Withanone on A549 and TIG-3 cells in combination. 
Garg et al. 2018 J Gerontol A Biol Sci Med Sci (Communicated) 
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Fig. 12. Effect of CucWi-N on cell survival and multiplication: Chart depicting selection of 1:500 
molar ratio dose of the combination for further in vitro analysis over 48 hrs. 
Garg et al. 2018 J Gerontol A Biol Sci Med Sci (Communicated) 
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Fig. 13. Effect of CucWi-N on cell survival and multiplication: Crystal violet stained A549 and 
TIG-3 cells demonstrating the effect of CucWi-N treatment on cell morphology over 48 hrs. 
Garg et al. 2018 J Gerontol A Biol Sci Med Sci (Communicated) 
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Fig. 14. Effect of CucWi-N on cell survival and multiplication: Clonogenicity assay 
demonstrating the effect of CucWi-N treatment on A549 cell colony forming capacity. 
Garg et al. 2018 J Gerontol A Biol Sci Med Sci (Communicated) 
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Fig. 15. Effect of CucWi-N on cell survival and multiplication: Cell proliferation assay 
demonstrating the effect of CucWi-N treatment on A549 and TIG-3 cell multiplication over 
72 hrs. 
Garg et al. 2018 J Gerontol A Biol Sci Med Sci (Communicated) 
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Fig. 16. Effect of CucWi-N on expression of key regulators of cell growth: evidence for selective 
growth inhibition in cancer cells treated with CucWi-N (high) for 48 hrs. 
Garg et al. 2018 J Gerontol A Biol Sci Med Sci (Communicated) 
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Fig. 17. Molecular expression of selective growth limiting potential of CucWi-N: 
Immunocytostaining analysis of cell growth and arrest proteins in A549 cells treated with 
CucWi-N (high) for 48 hrs. 
Garg et al. 2018 J Gerontol A Biol Sci Med Sci (Communicated) 
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Fig. 18. Molecular evidence for growth limiting potential of CucWi-N: Cell cycle analysis of 
A549 cells treated with CucWi-N (high) for 48 hrs. 
Garg et al. 2018 J Gerontol A Biol Sci Med Sci (Communicated) 
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Fig. 19. Molecular evidence of selective growth limiting potential of CucWi-N: Expression 
analysis for Lamin A/C by immunocytostaining in cells treated with CucWi-N with varying 
time periods. 
Garg et al. 2018 J Gerontol A Biol Sci Med Sci (Communicated) 
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Fig. 20. Induction of senescence and inhibition of expression of migratory proteins by CucWi-N: 
Serial passaging of A549 cells with CucWi-N (low) led to the induction of replicative 
senescence and growth arrest in 65 days. 
Garg et al. 2018 J Gerontol A Biol Sci Med Sci (Communicated) 
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Fig. 21. Induction of senescence and inhibition of expression of migratory proteins by CucWi-N: 
Immunoblotting analysis (left) and quantification (right) of cell growth and stress proteins in 
A549 cells serially passaged in CucWi-N. 
Garg et al. 2018 J Gerontol A Biol Sci Med Sci (Communicated) 
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Fig. 22. Induction of senescence and inhibition of expression of migratory proteins by CucWi-N: 
Mortalin ELISA analysis for mortalin quantification in A549 and doxorubicin-mediated 
senescent A549 cells treated with or without CucWi-N over 48 hrs. 
Garg et al. 2018 J Gerontol A Biol Sci Med Sci (Communicated) 
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Fig. 23. Induction of senescence and inhibition of expression of migratory proteins by CucWi-N: 
Immuncytostaining of DNA repair mechanism protein complex in A549 and doxorubicin-
mediated senescent A549 cells treated with CucWi-N (high) over 48 hrs. 
Garg et al. 2018 J Gerontol A Biol Sci Med Sci (Communicated) 
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Fig. 24. Inhibition of cell migration potential of the A549 cells by CucWi-N: Wound scratch 
migration assay and analysis of A549 cells treated with CucWi-N over 96 hrs. 
Garg et al. 2018 J Gerontol A Biol Sci Med Sci (Communicated) 
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Fig. 25. Inhibition of cell migration potential of the A549 cells by CucWi-N: Corning® 
BioCoatTM MatrigelTM invasion assay and analysis of A549 cells treated with CucWi-N over 
48 hrs. 
Garg et al. 2018 J Gerontol A Biol Sci Med Sci (Communicated) 
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Fig. 26. Inhibition of cell migration potential of the A549 cells by CucWi-N: Immunoblotting 
analysis (left) and quantification (right) of involved proteins in A549 cells treated with 
CucWi-N (low/high) for 48 hrs. 
Garg et al. 2018 J Gerontol A Biol Sci Med Sci (Communicated) 
 
 
 
	106	
	
	
 
 
 
Fig. 27. Inhibition of cell migration potential of the A549 cells by CucWi-N: Immuncytostaining 
of involved proteins in A549 cells treated with CucWi-N (low/high) for 48 hrs. 
Garg et al. 2018 J Gerontol A Biol Sci Med Sci (Communicated) 
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Fig. 28. In silico analysis of interactions of Cuc and Wi-N with mortalin protein involved in cell 
proliferation and migration: Docking simulation diagram of Cucurbitacin B with mortalin 
showing binding at interacts Thr267 and Gly269 lying within the p53 binding region. 
Garg et al. 2018 J Gerontol A Biol Sci Med Sci (Communicated) 
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Fig. 29. In silico analysis of interactions of CucWi-N with p53 tumor suppressor protein: 
Docking simulation diagram of Cucurbitacin B with p53 showing binding at interacts Thr118 
and Lys321 lying outside the mortalin binding region. 
Garg et al. 2018 J Gerontol A Biol Sci Med Sci (Communicated) 
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Fig. 30. In silico analysis of interactions of CucWi-N with different target proteins: Chart 
tabulating the specific binding energies Cuc, Wi-N, CucWi-N and controls with various 
target proteins. 
Garg et al. 2018 J Gerontol A Biol Sci Med Sci (Communicated) 
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Fig. 31. In silico analysis of interactions of CucWi-N with hnRNP-K regulator of cell migration 
protein: Docking simulation diagram of Cucurbitacin B with hnRNP-K. 
Garg et al. 2018 J Gerontol A Biol Sci Med Sci (Communicated) 
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Fig. 32. In silico analysis of interactions of CucWi-N with target proteins: Docking simulation 
diagram of Withanone with hnRNP-K. 
Garg et al. 2018 J Gerontol A Biol Sci Med Sci (Communicated) 
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Fig. 33. In silico analysis of interactions of CucWi-N with target proteins: Docking simulation 
diagram of CucWi-N with hnRNP-K showing stable hydrogen bond binding at the interact 
Lys87. 
Garg et al. 2018 J Gerontol A Biol Sci Med Sci (Communicated) 
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Fig. 34. In silico analysis of interactions of CucWi-N with target proteins: Immunocytostaining 
analysis of Cucurbitacin B, Withanone and CucWi-N (high) with hnRNP-K protein. 
Garg et al. 2018 J Gerontol A Biol Sci Med Sci (Communicated) 
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Fig. 35. In silico analysis of interactions of CucWi-N with target proteins: Immunoblotting 
analysis (left) and quantification (right) of Cucurbitacin B, Withanone and CucWi-N (high) 
with hnRNP-K protein. 
Garg et al. 2018 J Gerontol A Biol Sci Med Sci (Communicated) 
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Fig. 36. In vivo validation of anti-tumor activity of CucWi-N (1:10 weight ratio dose) treatment 
over 65 days: Representation of subcutaneous A549-xenograft suppressing effect of CucWi-
N. 
Garg et al. 2018 J Gerontol A Biol Sci Med Sci (Communicated) 
(Animal experiment approved by AIST Animal Ethical Committee) 
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Fig. 37. In vivo validation of anti-tumor activity of CucWi-N (1:10 weight ratio dose) treatment 
over 65 days: Graphical representation of weight and subcutaneous A549-xenograft size 
changes due to CucWi-N. 
Garg et al. 2018 J Gerontol A Biol Sci Med Sci (Communicated) 
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Fig. 38. In vivo validation of anti-tumor activity of CucWi-N (1:10 weight ratio dose) treatment 
over 65 days: Graphical representation of lung metastasis inhibition due to CucWi-N. 
Garg et al. 2018 J Gerontol A Biol Sci Med Sci (Communicated) 
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Fig. 39. In vivo validation of anti-tumor activity of CucWi-N (1:10 weight ratio dose) treatment 
over 65 days: Graphical representation of anti-oxidant and hemolytic activity of CucWi-N. 
Garg et al. 2018 J Gerontol A Biol Sci Med Sci (Communicated) 
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Fig. 40. In vivo validation of anti-tumor activity of CucWi-N (1:10 weight ratio dose) treatment 
over 65 days: Immunoblotting analysis (left) and quantification (right) of tumorigenesis-
promoting proteins in tumor lysates derived from animals treated with CucWi-N. 
Garg et al. 2018 J Gerontol A Biol Sci Med Sci (Communicated) 
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Chapter 6 
Quantitative and Qualitative Cell Viability Assay 
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6.1 Introduction 
Cancer is, most often, described as a continuous and sequential syndrome of diseases, where 
a normal cell acquires an immortal and immature state, and continues to divide uncontrollably.  It 
is discretely characterized and differentiated from the normal cells by their potential to immortality, 
growth in colonies, migrate, evade immune system and trigger angiogenesis [288].  One of the 
mainstay in cancer treatment is chemotherapy that usually ranges from months to years.  Its major 
objective is to eliminate or counterbalance the growth and function of the cancer cells without 
harming the normal cells in the body.  However most molecular targeted therapies are toxic to 
normal cells and often result into resistance and relapse [289].  Drug development involves 
extremely complicated route that initiates with simple viability/cytotoxicity assays performed on 
cultured cancer and normal cells.  Conventionally these assays are performed in short term (few 
hours to maximum 2-3 days) and rely on mitochondrial activity of viable cells that is linked to 
reliable quantitative read-outs.  These have been proved very informative for extremely toxic drugs 
that cause sudden death of cells by mechanisms including apoptosis, necrosis or autophagy.  
However, the drugs with slow, but still useful, action such as induction of growth arrest, senescence 
or differentiation require long term assessment [289-293]. 
In in vivo conditions, cancer cells grow from a single cell to a densely packed mass, subsequently 
the effect of anticancer molecule varies accordingly.  In order to mimic these conditions in a wet 
laboratory, it is essential to treat cells grown not only in sparse and dense monolayers, but also in 
colonies.  Furthermore, the effect of drugs may range from induction of stress, senescence, 
differentiation, or apoptosis that are usually interconnected.  An initial stressed state of the living 
cells might further result into either sensitization and death, or resistance.  Therefore, it is extremely 
important to take into account the morphology along with viability to implicate the effect on cell 
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proliferation.  Various metabolic-activity-based methods involving tetrazolium reduction, 
resazurin reduction, protease viability markers, ATP measurement, and real-time luciferase 
luminescence have been developed and described as reliable indicators of living cell viability.  
However, each one of these is tagged with its own set of advantages and disadvantages and lack 
ubiquitous application.  The most conspicuous factors limiting their use include concerns about 
specificity, cost, reagent-induced toxicity, operational interference, and reliability [294, 295]. 
Great investments have been apportioned to identification and development of potential 
anticancer candidates and to develop their regimens [296].  National Institutes of Health financial 
chart reported expenditure of about 5589 million US dollars in fiscal year 2016, out of which about 
10% was spent on research-related activities [297-299].  These stakes are not justified if they do 
not sum up into successful clinical trials.  Cancer toll is increasing with a speed that the American 
Cancer Society has already labeled it as the emerging epidemic [300].  This alarming scenario 
warrants rapid and elaborate investments in cancer drug discovery programs. Instead, the shrinking 
budget for medicinal research world-wide reflects lack of sophisticated instruments and personnel 
in small laboratories and offers additional constrains.  Under such compelling demand, an upgrade 
in the research methodology requiring lower cost and yielding more reliable outcomes will be 
extremely useful.  Based on these facts, we integrated the conventional cell viability assays in a 
way that one can take multiple read-outs from a simpler amalgamated experiment.  We demonstrate 
that our Quantitative and Qualitative Cell Viability (QCV) assay – is a substitute encompassing 
clonogenecity, cell viability and morphology readout as a single module and bypassing 
metabolism-based assays, especially applicable for compounds with color and longer mechanism 
of action – a novel, reliable and reproducible, relatively less expensive and simple technique for 
drug discovery programs. 
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6.2 Materials and methods 
6.2.1 Cell lines and reagents 
Cells purchased from DS Pharma/ JRCB, Japan were cultured either on Roswell Park 
Memorial Institute culture medium (RPMI, Life Technologies) (C6: rat brain glioma, DLD-1: 
colorectal adenocarcinoma and MKN45: human gastric carcinoma) or Dulbecco’s Modified 
Eagle’s culture medium (DMEM, Wako Chemicals) (A549: human non-small-cell lung carcinoma, 
DU145: human prostate adenocarcinoma, HeLa: human cervical adenocarcinoma, HT1080: human 
fibrosarcoma, MCF7: human breast adenocarcioma, MDA MB 231: human breast 
adenocarcinoma, Panc-1: human pancreatic epithelioid carcinoma, PLC/PRF/5: human hepatoma, 
SKOV-3: human ovarian adenocarcinoma, U2OS: human osteosarcoma, TIG-3: normal human 
lung fibroblasts and MRC5: normal human lung fibroblasts) or McCoy’s 5A culture medium (Life 
Technologies) (G361: human malignant melanoma).  
 
6.2.2 Generation of standard curve 
As presented in Fig.41, C6 cells (0, 5000, 10000, 20000, 40000, 80000 per well) were plated 
identically into two 12-well plates and incubated at 37°C and 5% CO2 for overnight to allow the 
cells adhere to the surface (Fig. 41).  Cells in plate 1 were trypsinized using EDTA-trypsin (50 µL) 
and suspended in growth medium (70 µL).  The cells were counted manually using cell counter 
(TC20™ Automated Cell Counter, Bio-Rad).  Simultaneously the cells in the plate 2 were fixed by 
incubating with ice cold methanol:acetone (1:1) for 3-5 minutes on ice, followed by washing with 
PBS and staining with 0.5% Crystal Violet at room temperature for 2-3 hours.  Stained cells were 
washed with PBS and allowed to air dry overnight.  To the air-dried colonies, 120 µL de-staining 
solution was added and mixed by gentle pipetting.  100 µL CV-homogenized solution was then 
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loaded into a 96-well plate to measure optical density at 570 nm using a spectrophotometer (Tecan 
Infinite 200® Pro, Tecan Group Ltd., Mannedorf, Switzerland).  Finally, a scatter graph was plotted 
using optical density against cell number to obtain c and m values for C6 cells (Fig. 42). 
 
6.2.3 MTT-based short-term viable cell microscopy 
Correlation between the changes in cell number and morphology as the result of treatment 
by an agent in a 96-well plate MTT-based cytotoxic assay was checked in C6 or U2OS cells.  1000 
cells per well were plated in a 96-well plate and allowed to settle overnight, followed by treatment 
with DMEM supplemented with or without colored cytotoxic extract labelled CN-04 or HA-05 
from our drug library.  The control or extract treated cells were incubated at 37°C and 5% CO2.  
After 48 hours cell pictures by a high resolution inverted microscope were recorded following 
which, 10 µL of 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma 
Chemical Corp, St. Louis, MO) in phosphate buffered saline (PBS; 2 mg/mL) was added to each 
well and incubated at same conditions for 4 hours.  All the media and dissolved MTT from the 
wells was aspirated and replaced with 100% DMSO, followed by measurement of optical density 
at 570 nm using Tecan Infinite 200 PRO (Tecan Group Ltd., Mannedorf, Switzerland). Cell 
viability and standard deviation were calculated using standard office software (Microsoft Office 
2016). 
 
6.2.4 MTT-based long-term cell viability assay 
Growth efficiency of live cells in a 96-well plate was determined by an MTT-based 
proliferation assay.  200, 400, 600, 800 and 1000 C6 cells per well were plated in 96-well plates 
(in 4 sets) and allowed to settle overnight, followed by change in growth medium DMEM every 
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alternate day.  Cells were incubated at 37°C and 5% CO2.  After every 48 hours, cell viability was 
calculated in one set each by employing the method described in the previous section.  At the end 
cell viability trend, standard deviation, slope equation and R2 values in all 4 sets were collectively 
calculated using standard office software (Microsoft Office 2016). 
 
6.2.5 Qualitative and Quantitative Cell Viability (QCV) assay  
C6 cells (100 per well) were plated in a 12-well plate and incubated at 37°C and 5% CO2 
for overnight to settle down. Individual cells were then allowed to grow into colonies in favorable 
conditions over the next 8-10 days (estimated duration for 15-20 population doublings for C6 cells).  
Culture medium with or without the colored extract CN-04 0.25-0.75% or colorless drug CB-01 
0.5% was changed every alternate day, until wide, visible, and viable colonies of cells were formed 
in the control group.  Cells were fixed using methanol:acetone (1:1) and stained with 0.5% crystal 
violet at room temperature for 2-3 hours, followed by 3 PBS washes and air drying overnight.  CV 
stained cell pictures were recorded by an inverted high resolution phase contrast microscope.  Dried 
assay plate was scanned and the colonies were manually counted.  120 µL de-staining solution was 
mixed to dissolve the CV stain from the cells, from which 100 µL was loaded into a 96-well plate 
to measure optical density at 570 nm using a spectrophotometer (Tecan Infinite 200® Pro, Tecan 
Group Ltd., Mannedorf, Switzerland). Using the equation {cell number = (OD – c)/m}, an average 
of long term cytotoxicity was obtained.  All calculations and graphs were obtained using standard 
office software (Microsoft Office 2016). 
 
6.2.6 Statistics 
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All the experiments were performed in triplicates, and the data were expressed as mean ± 
standard deviation. Statistical analysis was performed using GraphPad® software, Inc. (California, 
USA), based on independent experiments, and depicted as *<0.05, **0.01, and ***<0.001. 
 
6.3 Results 
We followed the protocol as indicated in the later section and tested in sixteen cancer cell 
lines (Fig. 42).  The optical densities in triplicates were plotted to obtain standard curves and slope 
(y-intercept values).  R2-value more than 98% was considered significant (more than 85% of 
standard deviation explained), keeping in mind that these values will be useful to quantitate optical 
density into absolute cell number [301, 302]. 
In our regular cell viability assays using MTT, we observed that drug response is driven by 
cell density to a large extent.  Hence we examined the effect of cell density to growth or drug 
response in a time dependent manner.  As shown in Fig. 43, the experiments initiated with 200 rat 
brain glioma C6 cells showed the most efficient growth in 8 days followed by cell density/adhesion 
dependent growth inhibition (Fig. 43).  Trend-line slope, y-intercept and R2 values drawn showed 
that only the 200-variant could qualify to be significant (criteria to qualify = R2 > 98%) (Fig. 44).  
However, 200 cells per well to begin a viability assay in a 96-well plate may be considered 
incompetent as a result of high probability of experimental errors.   
We next used plant extract HA-05 that possessed color.  In independent 48-hour MTT-
based assays, we found that its color interfered with the optical density (Fig. 45).  Whereas low 
doses of the extract showed cytotoxicity by means of optical density followed by an increment, 
microscopic evaluation showed a clear dose dependent decrease in the cell density and stressed 
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morphology in the cells.  Such errors in the readouts as a result of plating efficiency, color, or the 
space in a 6-7 mm diameter well, urge remodeling. 
To elucidate the differences in the experimental output between the MTT-based 48-hours 
assay and QCV assay, we subjected C6 cells to our extract CN-04 that possesses color.  MTT-
based readouts showed a discrepancy in the readings - they showed an increase in cell viability up 
to 0.25% concentration dose (Fig. 46) however, the cell observations under the microscope did not 
support these data.  Cells macroscopically looked to be stressed and dying with increasing dose of 
the extract.  In order to confirm the possibility of interference of the color, we placed only extract 
(without cells) in a 96-well plate and incubated overnight in the same conditions as the living cells, 
then we took the readouts in the same way after a 4-hour incubation with MTT dye.  We found that 
the optical density from the wells corresponded directly with the dose of the extract (Fig. 47).  To 
eliminate color based discrepancy in the MTT-based cell count, we performed our QCV assay 
using the same extract.  As shown in Fig. 48, cell viability (absolute cell count), morphological 
condition and the colony forming potential of the cells treated with CN-04 0.25-0.75% showed 
comprehensible consistency (Fig. 48). 
In order to further validate QCV assay for colorless agents, we performed colony formation 
assay using 0.5% of CB-01 (colorless cytotoxic extract).  Besides the decrease in clonogenic 
potential, we corroborated considerable difference in the morphology of the treated cells against 
the control group (Fig. 49).  Optical density readout after de-staining revealed long-term 
quantifiable cell viability.  Using the slope and y-intercept values given in Fig. 42, we calculated 
the absolute cell concentrations in control and treated cells (Fig. 49).  Moreover, we found that the 
reduction in clonogenicity and viability as a result of the treatment were not the same.  While only 
approximately 35% colonies (Fig. 49) remained after 8 days of treatment and culture, 65% cells 
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(Fig. 49) in total survived, indicating plausible presence of individual, scattered and unperceivable 
cells within the well.  Since these results suggest that the colony number and the absolute cell count 
are two separate entities, they must be noted separately. 
 
6.4 Discussion 
Conventional cell viability assays in cultured cells are the standard and essential step of 
drug discovery protocols.  However, these are complicated by drug and/or chromogen 
characteristics and interactions including crystallization, chemical interference, membrane 
permeability alteration, toxicity, and formazan fabrication as seen with variation in culture medium 
condition, serum and glucose concentration and protein content [303-305].  Such hurdles have been 
implicated for drugs including epirubicin, paclitaxel, docetaxel, cisplatin, sodium azide, imatinib, 
ursolic acid, chloroquine, rottlerin, curcumin, temozolomide, verampil, resveratrol, kaempferol, 
luteolin, quercetin, angiotensin, norepinephrine, amyloid b-peptide, interferon-gamma, glutathione 
S-transferase, nanoparticle-based medicines, and many more [306].  Furthermore, the mechanism 
of action for many natural anticancer drugs may be slower and hence demand time and dose 
dependent response over longer period [307].  In order to circumvent these difficulties and 
accommodate wide range of drugs, we assimilated the standard assays to yield quantitative and 
reliable readout from a prime experiment.  In our QCV assay, it is possible to examine the effect 
of drugs in short as well as longer span of time that also allows to investigate the effect of drug on 
clonogenic potential of cells.  Such readouts are more relevant to the cancer therapy regimens 
ranging from months to years [290, 292, 293, 308].  Furthermore, our QCV assay allows 
observations on cell morphology, an important factor to contemplate drug response characteristics 
and signalings [309-311].  Evaluation based on fixed cells make the use of methanol-based CV 
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stain solution more pertinent in this technique, accounting for absolute cell count instead of only 
the metabolically viable.  The multidimensional aspects of our assay depict its economic 
performance, an important criterion in the scenario of shrinking research budget and increasing 
need of anti-cancer drug screening and drug development from natural resources.  Taken together, 
QCV provides an easy way to obtain qualitative and quantitative read-outs of drug effect on cell 
viability in a reliable and reproducible way, with reduced efforts and time constrains. 
 
6.5 Protocol 
6.5.1 Equipment and reagents 
Cell counter; Spectrophotometer at 570 nm wavelength; Microscope; Incubator at 37°C 
with 5% CO2.  Prepare a 0.5% w/v crystal violet solution in distilled water with 25% v/v methanol 
- mix well and store at room temperature.  Prepare de-staining solution by mixing 15% v/v 
methanol and glacial acetic acid each in distilled water - mix well and store at room temperature. 
 
6.5.2 Generation of standard curve  
1. Plate 0, 5000, 10000, 20000, 40000, 80000 cells per well identically into two 12-well plates.  
Incubate at 37°C and 5% CO2 for cells to settle down (12-48 hours). 
2. Confirm the healthy cell condition under the microscope and proceed as follows –  
3. Plate 1 – trypsinize the cells using 50 µL EDTA-trypsin, neutralize reaction with 70 µL growth 
medium and count using cell counter. 
4. Plate 2 – Fix the cells by incubating with ice cold methanol:acetone (1:1) fixative for 3-5 
minutes on ice.  Wash the fixed cells with PBS and stain with 0.5% crystal violet at room 
temperature for 2-3 hours followed by washing with PBS and air dry.  Add 120 µL de-staining 
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solution and mix well.  Take 100 µL solution and load into a 96-well plate. Measure optical 
density at 570 nm using a spectrophotometer. 
5. Plot a scatter graph of the optical density from plate 2 against the cell number from plate 1.  
Find out the “y = mx + c”, where ‘c’ is the y-intercept and ‘m’ is the slope. 
 
6.5.3 QCV assay protocol 
1. Plate 100 cells per well in a 12-well plate.  Incubate at 37°C and 5% CO2 for cells to settle 
down. 
2. Treat the cells in appropriate conditions in plates and incubate for appropriate time. 
3. Fix the cells and stain with 0.5% crystal violet at room temperature for 2-3 hours. 
4. Wash the plate and let it air dry. 
5. Take cell pictures (for Cell morphology observation). 
6. Scan the cell plate and manually count the number of colonies (colony formation assay). 
7. Add 120 µL de-staining solution and mix well.  Take 100 µL solution and load into a 96 
well plate.   Measure optical density using a spectrophotometer at wavelength 570 nm.  Use the 
equation {cell number = (OD – c)/m} to find out the number of cells (= long-term treatment 
cytotoxicity / cell viability). 
 
6.5.4 General considerations 
Calibration of instruments and technique is recommended prior to operation.  The 
incubation time for cell adherence, cytotoxicity and population doubling should be standardized 
for best outcomes. Troubleshooting guide is tabulated in Fig. 50. 
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Fig. 41. Schematic presentation of the protocol: Top - Determination of standard curve and slope 
equation; bottom - QCV assay to determine cell viability, colony forming potential and cell 
morphology after long-term culture of cells. 
Garg et al. 2018 BMC Research Notes 11(1): 403 
	132	
	
	
 
 
 
 
 
Fig. 42. QCV standardization and determination of slope/y-intercept and R2 value in 16 cancer 
cell lines. 
Garg et al. 2018 BMC Research Notes 11(1): 403 
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Fig. 43. Interference of cell number and color of the test reagent in the cytotoxicity assays using 
conventional MTT assay - Cell viability after 8 days of culture in a 96-well plate well. 
Garg et al. 2018 BMC Research Notes 11(1): 403 
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Fig. 44. Interference of cell number and color of the test reagent in the cytotoxicity assays using 
conventional MTT assay - Cell growth pattern over 8 days in a 96-well plate. 
Garg et al. 2018 BMC Research Notes 11(1): 403 
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Fig. 45. Interference of cell number and color of the test reagent in the cytotoxicity assays using 
conventional MTT assay - Cell viability after 48 hours treatment with colored extract HA-05 
(left) and cell pictures (right) against control. 
Garg et al. 2018 BMC Research Notes 11(1): 403 
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Fig. 46. Determination of cytotoxicity of a colored reagent by conventional MTT assays and 
institution of QCV assay - Viability of cells treated with the reagent for 48h showed 
haphazard pattern, while the cell pictures showed dose-dependent cytotoxicity. 
Garg et al. 2018 BMC Research Notes 11(1): 403 
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Fig. 47. Determination of cytotoxicity of a colored reagent by conventional MTT assays and 
institution of QCV assay - Dose-dependent increase in optical density was observed as a 
result of color of the reagent. 
Garg et al. 2018 BMC Research Notes 11(1): 403 
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Fig. 48. Determination of cytotoxicity of a colored reagent by conventional MTT assays and 
institution of QCV assay - Colony number determined by dissolving crystal violet stain, and 
the morphology of the cells correlated with each other proportionately. 
Garg et al. 2018 BMC Research Notes 11(1): 403 
 
 
	139	
	
	
 
Fig. 49. Determination of cytotoxicity of a colored reagent by conventional MTT assays and 
institution of QCV assay - Quantitative cell number determined by dissolving crystal violet 
stain, and the morphology of the cells correlated with each other proportionately. 
Garg et al. 2018 BMC Research Notes 11(1): 403 
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Fig. 50. Validation of QCV Assay: Crystal violet stained cell pictures at the end of 8 days 
treatment are shown (top left); manually counted cell colonies in six variants of control and 
treated wells (top right); quantified colony number (bottom left); quantified absolute cell 
count by dissolving crystal violet in de-staining solution and using slope equation for C6 
cells (bottom right). 
Garg et al. 2018 BMC Research Notes 11(1): 403 
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Fig. 51. Troubleshooting guide for QCV assay. 
Garg et al. 2018 BMC Research Notes 11(1): 403 
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Chapter 7 
Conclusions 
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Stress is a pathological response of living tissue to an external stimulus. These stimuli can 
range from chemicals, radiations and hormones to genetic conditions. In an attempt to fight the 
stressors, the living tissue may sometimes undergo a physiological or pathological change, which 
may develop into a disease. These changes may be acute, chronic, or even permanent. Many stress 
related phenomena have been identified –early aging, cancer, neuro-degeneration, melanogenesis, 
inflammation, etc. These warrant continual interventions and updating. Considerable progress has 
been made in gene-targeted therapeutic approaches in the last few decades. However, undesired 
toxicity of synthetic drugs, drug resistance, spread of disease and recurrence pose serious hurdle to 
its treatment and prognosis.  
Several studies have indicated that stress is tightly connected to carcinogenesis. Cancer is 
a complex disease, most consistently defined as uncontrolled and indefinite proliferation of cells. 
Customary treatments include surgery, radio- and chemo-therapies involving removal or killing of 
cancer cells, respectively. Cancer represents a highly stressed physiological state in which the cells 
escape the stress-signaling mediated growth arrest. Natural compounds have recently attracted 
attention due to their safety and economic aspects. We screened some natural purified compounds 
for anti-stress and anti-cancer potential. We anticipated that in addition to their value for cancer 
therapy, these may also possess cancer-preventive potentials. The later constitutes a highly 
prioritized field of research in the current scenario of (i) increasing levels of stress due to high use 
of chemicals in our daily living and (ii) increasing old age societies world-wide. We identified 
candidate compounds that showed enhanced cytotoxicity to the cancer cells, such as the 
combination of Cucurbitacin B and Withanone and tamarind seed extracts. In the process of initial 
screening, we encountered the discrepancies and the results, and later found that this was due to 
the color of the compounds/extracts we used. 
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In the first route of exploration, we invented, developed, verified and proposed a technique 
as an upgrade from the conventional chromogen-related methods – quantitative and qualitative cell 
viability assay (QCV assay). Often the herbal extracts and the purified active components possess 
color that interferes with such quantitative cytotoxicity estimation.  Furthermore, their action is 
rather slow/gradual and requires long term assays such as effect on clonogenic potential of cells in 
1-2 weeks, which cannot be performed in 96-well plate and hence the quantitative assessments are 
fairly difficult.  At the same time, the visual observations of cell morphology hold significant hints 
to molecular signaling underlining the effect of drugs. Our broad-spectrum QCV assay has the 
capacity to present the long-term cytotoxicity results along with clonogenicity and morphological 
assessment of the cells. 
In second path, we screened tamarind seed extracts and found their potential as potent anti-
melanogenesis medicine (details not shown). We obtained tamarind seed extracts by 95% ethanol 
and water extraction. In cell based assays, we found that the extracts were safe for both cancer and 
normal cells (in the range of 0.01-1.0%, for at least 4 weeks). Consistently, molecular studies 
revealed no effect on the expression/activity of tumor suppressor proteins.  We next recruited 
oxidative stress models; hydrogen peroxide (H2O2), ultraviolet radiation (UV) and diacylglycerol 
1–oleoyl-2-acetyl-sn-glycerol (OAG) and investigated the anti-stress potential of the extracts and 
found that whereas the extracts did not offer any protection to stress caused by H2O2 or UV, they 
significantly compromised OAG induced melanogenesis. 
Towards our final step, we developed a combination of Cucurbitacin B (from Helicteres 
angustifolia, Chinese Ginseng) and Withanone (from Withania somnifera, Indian Ginseng), and 
analyzed its anticancer potency, mechanism of action with particular focus to non-small-cell lung 
cancer. We performed cell culture assays including short-term and long-term viability, migration 
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and invasion assays. Molecular markers defining each of the phenotype were analyzed by Western 
blotting or immunocytostaining with specific antibodies. We found that 1:500 molar ratio 
combination (called CucWi-N) of Cucurbitacin B and Withanone possessed potent anticancer 
activity as compared to each of the compounds. In silico analysis revealed that Cucurbitacin B 
abrogates mortain-p53 interactions resulting in activation of tumor suppressor activity of p53. At 
sub-toxic dose Cucurbitacin B showed synergistic affinity with Withanone to target hnRNP-K 
protein (necessary for cancer cell migration). In in vitro analysis, we found that whereas 
Cucurbitacin B alone was more cytotoxic to the normal cells, its combination with Withanone 
significantly and dose-dependently caused changes at cellular and protein level indicating 
inhibition of stemness and aggressiveness of the cancer cells and induction of replicative 
senescence. Due to the selectivity of the drugs, at a dose safe to use for the normal cells, the 
combination via inhibition of mortalin and hnRNP-K combination caused DNA damage and 
inhibited lamin A/C. This stimulated DNA repair mechanism with higher expression of lamin-A/C 
and PARP 1, and resulted into gradual cellular senescence. In the senescent cells, the combination 
inhibited the repair mechanism by inhibited MRE-Rad50-NBS1 complex. Finally, it also inhibited 
a number of stem-cell, migratory and invasiveness markers to be called as a potent anti-metastatic 
cancer formulation. We sincerely believe that the CucWi-N is a potential anticancer drug that 
warrants further mechanistic and clinical studies, and has been so far a significant contribution to 
science. 
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